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ABSTRACT

Various embodiments provide methods and related compositions for increasing the population size ofhematopoietic stem
cells (HSCs) in patients that may benefit from reconstitution
of stem cells and/or differentiated cells of the blood lineage.
The present methods enable the production ofHSCs ex vivo
and in vivo by reducing latexin expression and/or latexin
activity within HSC exposed to various antagonists. Inhibition of latexin expression and/or latexin activity by various
antagonists can promote HSC proliferation and/or inhibit
HSC apoptosis. Antagonists that can reduce latexin expression and/or latexin activity can be utilized to regenerate
endogenous HSCs within patients affected with disorders,
diseases, cancers, or therapies for such conditions, that result
in the depletion or reduction in HSCs.
3 Claims, 17 Drawing Sheets
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EX VIVO AND IN VIVO METHODS AND
RELATED COMPOSITIONS FOR
REGENERATING HEMATOPOIETIC STEM
CELL POPULATIONS

(e.g., typically less than 8 weeks in a mouse) prior to undergoing full differentiation. HSCs can differentiate into
hematopoietic progenitor cells ("HPCs") that can further differentiate into clonogenic cells, or cells of a single lineage.
For example, the differentiation of common lymphoid progenitors ("CLPs") can produce T lymphocytes ("T cells"), B
lymphocytes ("B cells"), and natural killer cells ("NKs"). The
differentiation of common myeloid progenitors ("CMPs")
can generate blood cells of other lineages, including erythrocytes, macrophages, granulocytes, and platelets. The maintenance of mature blood-borne cells in the peripheral circulation is critical for various processes, including oxygen
delivery and immunological protection.
Bone marrow transplantation ("BMT") and hematopoietic
stem cell transplantation ("HSCT") can be effective for the
treatment of diseases of the blood, diseases of the bone marrow, cancers of the blood, and cancers of the bone marrow,
including various types of anemia, leukemia, and immunological disorders. For example, obtaining HSCs by bone marrow harvesting from donors can be technically challenging in
that harvesting sufficient material from the bone marrows of
donors involves multiple insertions oflarge needles to obtain
sufficient amount of stem cells. Methods for regenerating
HSCs can be useful for treating patients affected by various
types of disorders, diseases, or cancers that deleteriously
affect the number of endogenous HSCs within a patient.

5

CROSS-REFERENCES
This application is a divisional ofU.S. application Ser. No.
11/540,641, filed Oct. 2, 2006, which is a non-provisional
application that claims priority under 35 U.S.C. § 119 to U.S.
Provisional Application No. 60/722,755 entitled MANIPULATION OF ADULT STEM CELL POPULATION SIZES
BY LATEXIN and filed on Sep. 30, 2005, the entire content
of which are hereby incorporated by reference.

10

15

STATEMENT OF GOVERNMENT INTEREST
This invention has been made with Government support
under grant number ROIAG024950, awarded by the National
Institute on Aging. The government has certain rights in the
invention.

20

TECHNICAL FIELD
The present invention relates to methods for regenerating
adult hematopoietic stem cells (HSCs) and related compositions by reducing/inhibiting latexin expression and/or latexin
activity.

25

INCORPORATION-BY-REFERENCE & TEXTS

30

The material on the accompanying CD-R is hereby incorporated by reference into this application. The accompanying
compact disc contains one file, 1028750-000249
HSCS.ST25.txt, which was created on Oct. 2, 2006. The file
named 1028750-000249 HSCS.ST25.txt is 5 KB. The file can
be accessed using Microsoft Word on a computer that uses
Windows OS.

35

BACKGROUND OF THE INVENTION

40

Hematopoiesis is a complex process for producing multiple and distinct lineages ofblood-borne cells throughout the
life span of an organism. Hematopoietic stem cells ("HSCs")
represent a subset of undifferentiated cells that resides predominantly in the bone marrow of adult mammals. HSCs, as
a population, are capable of self-renewal by maintaining a
sufficient number of HSCs within an organism's bone marrow as a reservoir of uncommitted cells that can be further
differentiated into various types of new blood cells. Such
newly generated blood cells emerge from the bone marrow
and enter the circulatory system in order to continuously
replace mature/aging circulating blood cell types. The ability
of HSCs, as a population, to differentiate and to give rise to
cells of multi-lineages is critical for the preservation of an
organism.
In order for the maintenance of steady-state hematopoiesis,
a balance must be achieved between the rate of self-generation (i.e., for maintaining a steady supply of HSCs) and the
rate of differentiation (i.e., for replenishing senescent cells).
Hematopoiesis occurs as a developmental continuum in that a
given population of HSCs is representative of a heterogeneous mixture of cells, mainly composed oflong-term HSCs
("LT-HSCs") and short-term HSCs ("ST-HSCs"). LT-HSCs
are stem cells that have the capacity for self-renewal throughout the life span of an organism. However, ST-HSCs exhibit
transient self-renewal properties for a limited period of time

SUMMARY OF THE INVENTION

45

50

55

60

65

An ex vivo method for producing a renewed population of
hematopoietic stem cells (HSCs) is provided, in which a first
HSC population from a donor is obtained, the first HSC
population is contacted with an antagonist that reduces
latexin expression and/or latexin activity, and the HSC population is cultured under in vitro conditions that can promote
cell proliferation and/or inhibit apoptosis to obtain a second
HSC population that comprises a progeny of the first HSC
population.
A method for reconstituting a recipient host with a HSC
population generated ex vivo is provided, in which a first HSC
population from a donor is obtained, the first HSC population
is contacted with an antagonist that reduces latexin expression and/or latexin activity, the HSC population is cultured
under in vitro conditions that can promote cell proliferation
and/or inhibit apoptosis to obtain a second HSC population
that comprises a progeny of the first HSC population, and the
second HSC population is transplanted to the recipient host in
need ofHSC reconstitution.
A method for reconstituting a recipient host with a HSC
population generated in vivo is provided, in which the recipient host is administered with a pharmaceutical composition
comprising an antagonist that reduces latexin expression and/
or latexin activity.

BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 illustrates various biochemical pathways mediated
by latexin that may be involved in the regulation of HSC
proliferation in mammals, as described in Example 1.
FIG. 2 illustrates a genomic map of congenic intervals
identified in reciprocal Chr.3 congenic mouse strains, as
described in Example 1.
FIG. 3 illustrates a genome-wide linkage analysis based on
GeneNetwork that associates the trait regulating HSC population size with three quantitative trait loci (QTL) on Chromosomes (Chr) 3, 5, and 18, respectively, as described in
Example 4.

US 9,284,530 B2
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FIG. 4A illustrates the CAFC day 35 frequency observed
for femur cells of Chr3 congenic mice compared to background mice, as described in Example 5.
FIG. 4B illustrates the CAFC day 35 frequency observed
for LSK cells of Chr3 congenic mice compared to background mice, as described in Example 5.
FIG. 4C illustrates the effect ofD2 alleles on the number of
long-termrepopulating HSCs in B.D Chr3 mice, as described
in Example 5.
FIG. SA illustrates that D2 alleles confer an increase in
HSC replication and that B6 alleles confer a decrease in HSC
replication, as described in Example 6.
FIG. SB illustrates the effect ofChr3 QTL on the cell-cycle
kinetics of hematopoietic progenitor cells (HPCs), as
described in Example 6.
FIG. SC illustrates that D2 alleles of the Chr 3 QTL confer
HSCs with higher self-renewal capability, as described in
Example 7.
FIG. SD illustrates bone marrow LSK cells subject to apoptosis as detected by Annexin V-staining, as described in
Example 8.
FIG. SE illustrates the effect of Chr 3QTL on apoptosis of
LSK cells in steady-state B6 D2 and Chr3 congenic bone
marrows, as described in Example 8.
FIG. 6A illustrates Lxn mRNA expression in congenic
LSK cells compared with B6 and D2 cells, as described in
Example 10.
FIG. 6B illustrates quantitation ofLxn transcripts by realtime PCR in peripheral blood leukocytes, whole bone marrow, Lin-negative bone marrow cells, and LSK stem cells, as
described in Example 11.
FIG. 6C illustrates immunoreactivity between the antimouse LXN antibody and a protein (29 kD) from bone marrow cells by a Western Blot, as described in Example 12.
FIG. 6D illustrates the levels ofLXN protein in whole bone
marrow and Lin-negative cells, as described in Example 12.
FIG. 7A illustrates various QTLs that may be involved in
the regulation ofLxn expression, as described in Example 13.
FIG. 7B illustrates a CpG island analysis in the upstream
sequence of Lxn open-reading frame, as described in
Example 13.
FIG. SA illustrates a schematic for in vitro infection of
bone marrow cells with retroviral vectors containing either
GFP or Lxn (Lxn-GFP), and subsequent transplantation into
irradiated mouse recipients, as described in Example 14.
FIG. SB illustrates results of a Western blot analysis of
GFP+ cells sorted from the BM of the recipient mice transplanted with either Lxn-GFP or GFP-transduced cells, as
described in Example 14.
FIG. SC illustrates results ofCAFC day35 frequency assay
ofD2 bone marrow cells transduced with either GFP control
or Lxn-GFP, as described in Example 14.
FIG. SD illustrates results of long-term repopulating cells
(LTRC) frequency assay of B.D Chr.3 congenic BM cells
transduced with either GFP control or Lxn-GFP, as described
in Example 14.
FIG. 9A illustrates exemplary SiRNAs transfected into
NIH3T3 cells, as described in Example 15.
FIG. 9B illustrates the results of sequence-specific SiRNAmediated inhibition of latexin mRNA expression in mouse
adult stem cells that resulted in HSC proliferation and HSC
apoptotic inhibition, as described in Example 15.

(HSCs) within a patient in need of HSC renewal. For
example, the present methods are useful for the treatment of
patients affected with disorders, diseases, and/or cancers that
deleteriously compromise the number of endogenous HSCs
and differentiated forms of such HSCs within patients.
Examples of disorders, diseases, and/or cancers contemplated for treatment by the present methods and compositions
include diseases of the blood, diseases of the bone marrow,
cancers of the blood, and cancers of the bone marrow, including various types of anemia, leukemia, immunological disorders, thalassemia major, sickle-cell disease, myelodysplastic
syndrome, lymphoma, aplastic anemia, and multiple
myeloma. Patients that may benefit from treatments that utilize the present methods and related compositions include
candidates for bone marrow transplantation ("BMT") and
hematopoietic stem cell transplantation ("HSCT"). Transplantation therapies can be effective for the treatment of various types of leukemia and any disorder/disease/cancer for
which patients are subjected to radiotherapy and/or chemotherapy. The renewed or regenerated population ofHSCs that
can be induced by the present methods and compositions are
useful for various applications, including regenerative medicine, tissue engineering, tissue repair, cancer therapy, and
gene therapy. As described in the following embodiments, a
given HSC population obtained from a donor or within a
recipient host (i.e., a patient) can be induced to proliferate
and/or to suppress apoptosis by providing antagonistic compounds/compositions that can inhibit latexin expression and/
or latexin activity.
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DETAILED DESCRIPTION OF THE INVENTION
65

Various embodiments provide methods and related compositions useful for reconstituting hematopoietic stem cells

As used throughout the specification and the appended
claims, the terms listed below have the following meanings,
wherein "a" means one or more:
The terms "hematopoietic stem cells" ("HSCs") refer to a
heterogeneous mixture of undifferentiated progenitor stem
cells, mainly composed oflong-term HSCs ("LT-HSCs") and
short-term HSCs ("ST-HSCs"). LT-HSCs are undifferentiated stem cells that have the capacity for self-renewal
throughout the life span of an organism. ST-HSCs are undifferentiated stem cells that have the capacity for self-renewal
for a limited time prior to full differentiation into a specific
lineage. For example, HSCs can differentiate into hematopoietic progenitor cells ("HPCs") that can further differentiate
into clonogenic cells, or cells of a single lineage, that represent a subset of a hematopoietic lineage. HSCs include nonembryonic stem cells isolated from post-natal animals. HSCs
include "pluripotent adult stem cells" isolated from the bone
marrows of mammals that are capable of differentiating into
tissues of all three germ or dermal layers, such as the mesoderm, endoderm, and ectoderm. A "pluripotent stem cell"
refers to a stem cell that exhibits the capacity to grow into any
type of cell that constitutes an organism. A pluripotent cell
can be self-renewing and can remain dormant/quiescent
within a tissue. HSCs include "multipotent stem cells" that
exhibit the capacity to grow into any subset of cells that
constitute an organism. HSCs include undifferentiated stem
cells that exhibit a distinct profile of cell surface markers,
including the following combination of markers: Thy-1 10 Seal+ Lineage- c-kit+; or CD 150+ CD48- Sea-l+ Lineage- c-kit+;
orThy-1 1° CD150+ CD48- Sea-l+ Lineage- c-kit+ (Kiel eta!.,
Cell, Vol. 121, p 1109-1121 (2005)). HSCs that express the
combination of human counterparts for these markers are
preferably contemplated. The following references are herein
incorporated by reference in their entirety: Cheshier et a!.,
P.N.A.S., Vol. 96, p 3120-3125 (1999); Eckfeldtetal., Nature,
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Vol. 6, p 726-737 (2005); Wright et. a!., Science, Vol. 94, p
1933-1936 (2001 ); and Preston eta!., J. Clin. Pathol. Vol. 56,
p 86-96 (2003).
The term "first HSC population" refers to HSCs obtained
from a donor, wherein the first HSC population expresses cell
surface markers as described in [0036].
The term "second HSC population" refers to the progeny of
the first HSC population produced by in vitro cell proliferation under in vitro conditions, wherein the second HSC population expresses cell surface markers as described in [0036].
The term "latexin" ("Lxn") refers to the Lxn gene, isoforms/variants of the Lxn gene, and gene products derived
from the Lxn gene, including messenger RNA and protein.
The sense-strand of a human latexin eDNA is provided as
SEQ ID NO: 1. A human latexin protein sequence is provided
as SEQ ID N0:2. Latexin isoforms/variants include genes
containing exon sequences having at least about 70%, 75%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence
similarity to SEQ ID NO: 1; genes containing exon sequences
having at least about 70%,75%,80%, 85%, 90%, 95%,96%,
97%, 98%, or 99% sequence identity to SEQ ID NO: 1; those
sequences encoded by genes containing exon sequences having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%,
97%, 98%, or 99% sequence similarity to SEQ ID NO: 1;
those sequences encoded by genes containing exon
sequences having at least about 70%, 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID
NO: 1; those sequences having at least about 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence similarity to SEQ ID N0:2; and those sequences having at least
about70%, 75%,80%,85%,90%,95%,96%,97%, 98%,or
99% sequence identity to SEQ ID N0:2. Latexin isoforms/
variants include mammalian homo logs listed in Tables 1-3 as
described in [0076]. Examples of latexin isoforms/variants
include the carboxypeptidase inhibitor (CARIN) described in
U.S. Pat. No. 5,998,373.
The term "antagonist" refers to any compound or composition that can inhibit the expression and/or the activity of
latexin and latexin isoforms, including sequence-specific
polynucleotides that can interfere with the transcription of
endogenous latexin gene; sequence-specific polynucleotides
that can interfere with the translation of latexin mRNA transcripts (e.g., siRNAs, ribozymes ); sequence-specific
polypeptides that can interfere with the protein stability of
latexin, the enzymatic activity of latexin, and/or the binding
activity oflatexin with respect to substrates and/or regulatory
proteins; and small molecule compounds that can interfere
with the protein stability oflatexin, the enzymatic activity of
latexin, and/or the binding activity of latexin. An effective
antagonist can promote HSC proliferation by at least 25%,
30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,
80%, 85%, 90%, 95%, or 100%. An effective antagonist can
suppress HSC apoptosis by at least 25%, 30%, 35%, 40%,
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, or 100%.

ing HSC cell proliferation (i.e., HSC self-renewal) and/or by
suppressing HSC apoptosis, as seen in B.D Chr3 congenic
mice. In contrast, the B6 alleles conferred a decrease in HSC
population size. Differential expression levels conferred by
these alleles correlated with the latexin ("Lxn") gene locus.
Differentiallatexin expression levels were shown to inversely
correlate with HSC population size, based on experimental
data obtained utilizing oligonucleotide arrays (e.g., microarrays), real-time PCR, and Western blots. Ectopic expression
of latexin protein from a retroviral construct resulted in a
decrease in stem cell population size. Clusters of single nucleotide polymorphisms (SNPs) were identified upstream of the
Lxn transcriptional start site. At least two of these clusters
appear to be associated with potential binding sites fortranscription factors involved in hematorpoietic stem cell regulation. Thus, promoter polymorphisms between B6 and D2
alleles appear to affect Lxn gene expression, and consequently, to influence HSC population size. The results of
these experiments are presented in FIGS. 1-9 and are further
described in Examples 1-15.
Latexin was identified initially as an antigen expressed
within the rat cerebral cortex. Latexin mRNA and protein (29
kDa) have been shown by others to be expressed in neural and
non-neural tissues. Latexin exhibits inhibitory activity
against rat carboxypeptidase AI ("CPA!"), carboxypeptidase
A2 ("CPA2), and mast-cell CPA (Uratani eta!., Biochem. J.,
Vol346: 817-826 (2000). CPA and CPB are pancreatic zinccontaining proteolytic enzymes that catalyze the hydrolysis
of the carboxyl-terminal peptide bond within polypeptide
chains. Carboxypeptidase activities can be regulated either by
endogenous protein inhibitors or by enzymatic cleavage of a
segment of a propeptide that releases the active form of the
carboxypeptidase. Both latexin and Tissue Carboxypeptidase
Inhibitor (TCI) are examples of endogenous protein inhibitors of carboxypeptidases. Latexin and TCI contain several
potential phosphorylation sites, and both are expressed and
localized in the cytosol of a number of tissues, including the
brain, the lung, and the digestive tract.
FIG. 1 illustrates various biochemical pathways mediated
by latexin that may be involved in the regulation of HSC
proliferation in mammals. Lxn is the only known endogenous
carboxypeptidase A (CPA) inhibitor in mammals. Structural
similarity between latexin and cystatins that inhibit cathepsins in the lysosomal protein degradation pathway suggests
an inflammatory role of latexin in activated macrophages.
Thus, latexin may be involved in the metabolism of specific
proteins that are essential for HSC functions. Lxn appears to
exhibit two potential Ca2+/calmodulin-dependent protein
kinase sites and one c-GMP-dependent protein kinase phosphorylation site. Thus, the c-GMP/PKG and/or calcium/
calmodulin signaling pathways may be involved in the Lxnmediated regulation of HSCs. The physical structure of
latexin includes two nearly identical domains that have high
conformational homology with the cystatins that can inhibit
cathepsins in the lysosomal protein degradation pathway.
Thus, Lxn appears to have an inflammatory role in activated
macrophages, and to be involved in the metabolism of specific proteins that are essential for HSC functions. The
c-GMP/PKG and/or calcium/calmodulin signaling pathways
may be involved in Lxn-mediated regulation ofHSCs based
on the fact that Lxn contains two potential Ca2+/calmodulin
dependent protein kinase sites and one c-GMP-dependent
protein kinase phosphorylation site. These possible pathways
may act synergistically or independently in the regulation of
HSC cycling, apoptosis, and/or proliferation that affect HSC
population size.
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II. Regulation of Cell Cycling, Apoptosis, and
Proliferation of Hematopoietic Stem Cells (HSCs)
Mediated by Latexin
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The present inventors have identified a quantitative trait
loci ("QTL") that confers variation in HSC numbers in young
and adult C57BL/6 (B6) and DBA/2 (D2) mice. By utilizing
reciprocal Chromosome 3 congenic mice derived from these
two parental strains, such as B.D Chr3 and D.B Chr3 mice,
the present inventors have demonstrated that introgressed D2
alleles confer an increase in HSC population size by enhanc-
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The mechanism for transcriptional regulation of latexin
appears to be related to the unique molecular architecture of
the Lxn gene locus, that includes multiple SNPs within potential regulatory regions. The Lxn gene locus is located within
an intron of Gfml, a gene that encodes a translational elongation factor in mitochondria. Because Gfml was not differentially expressed amongst the congenic and background
strains investigated, the differential transcriptional regulation
of the embedded Lxn was unique. The specific promoter
and/or enhancer regions of Lxn appear to be highly genespecific and to enable differential gene regulation. A potential
mechanism for differential gene expression between B6 and
D2 alleles is suggested by the identification of clusters of
confirmed SNPs sites within the potential promoter region of
Lxn that are spatially concordant with two putative binding
sites for transcription factors known to regulate stem cells.
For example, a cluster of SNPs (SNPs 1-3) in the canonical
Lxn promoter region is consistent with a region identified by
ESPEER as potentially possessing regulatory activity. The
SNP2 is located in the middle of the canonical core binding
site in one of two adjacent potential binding sites for the
transcription factor CBFl. The CBFl is associated with the
Notch-signaling pathway, known to be play a role in the
regulation of stem cell population size. The SNPs 10 and 11
are in close proximity, or reside within potential regulatory
regions, identified by ESPERR and TraFaC. The HNFl/
TCFl, a transcription factor with two adjacent binding sites
close to SNPll, can mediate events downstream of the
canonical Wnt/beta-catenin-signaling pathway known to be
involved in HSC regulation and to interact with the Notchsignaling pathway.

erably obtained from human donors, however, non-human
donors are also contemplated, including non-human primates, pigs, cows, horses, cats, and dogs. A purified population of HSCs may be obtained by utilizing various methods
known by persons skilled in the art and described in U.S. Pat.
No. 5,677,136; and U.S. Patent Publication No. 2006/
0040389, which are incorporated by reference in their
entirety.
Suitable antagonists include SiRNAs, ribozymes, antisense oligodeoxynucleotides, and small molecule compounds that can reduce latexin expression and/or latexin
activity. Examples of suitable antagonists and methods for
producing or identifYing such antagonists are described
below in Subsection C. A therapeutically effective latexin
antagonist can promote HSC proliferation and/or suppress
apoptosis by at least 25%. Suitable antagonists are further
defined above in Subsection I.
Contacting the first HSC population with an antagonist that
reduces latexin expression and/or latexin activity can promote cell proliferation and/or inhibit apoptosis provided that
the first HSC population is cultured under suitable in vitro
conditions. Latexin expression and/or latexin activity include
intracellular processes that regulate latexin promoter activation, transcriptional activation, transcriptional termination,
post-transcriptional processing, translational initiation, translational elongation, translational termination, and post-translational modification. Examples of suitable in vitro conditions are provided in U.S. Patent Publication No. 2005/
0214262; U.S. Patent Publication No. 2006/0030041; and
U.S. Patent Publication No. 2006/0030041, which are incorporated by reference in their entirety.
Latexin isoforms/variants suitable for antagonist-mediated
targeting are provided above in [0039] in Subsection I.
In another embodiment, a HSC population produced by the
present methods is disclosed, in which the HSCs comprise
any of the following combination of cell surface markers
characteristic of HSCs: Thy-1 10 Sea-l+ Lineage- c-kit+; or
CD150+ CD48- Sea-l+ Lineage- c-kit+; orThy-1 1° CD150+
CD48- Sea-l+ Lineage- c-kit+.
Various embodiments provide methods for reconstituting a
recipient host with a population of hematopoietic stem cells
(HSCs) generated ex vivo, in which the method comprises
obtaining a first HSC population from a donor, contacting the
first HSC population with an antagonist that reduces latexin
expression and/or latexin activity, culturing the HSC population under in vitro conditions that promote cell proliferation
and/or inhibit apoptosis to obtain a second HSC population
comprising a progeny of the first HSC population, and providing the second HSC population to the recipient host in
need ofHSC reconstitution.
The present methods are useful for the treatment of a
recipient host affected with a disease of the blood, a disease of
the bone marrow, a cancer of the blood, and a cancer of the
bone marrow, an immunological disorder, anemia, leukemia,
thalassemia major, sickle-cell disease, myelodysplastic syndrome, lymphoma, aplastic anemia, and/or multiple
myeloma. Disorders suitable for treatment by the present
methods include disorders that reduce the number of endogenous HSC population, such as genetic disorders that result in
sub-optimal number of HSCs, cancers that result in suboptimal number of HSCs, post-irradiation conditions that
result in sub-optimal number of HSCs, and post-chemotherapy conditions that result in sub-optimal number of
HSCs.
The HSC population generated ex vivo by the present
methods are transferred into a recipient host in need ofHSC
reconstitution. Such HSC populations that have been exposed
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A. Ex Vivo Methods
Various embodiments provide ex vivo methods for producing a renewed population ofhematopoietic stem cells (HSCs)
in which the method comprises obtaining a first HSC population from a donor, contacting the first HSC population with
an antagonist that reduces latexin expression and/or latexin
activity, and culturing the HSC population under in vitro
conditions that promote cell proliferation and/or inhibit apoptosis to obtain a second HSC population that comprises a
progeny of the first HSC population.
The first HSC population and the second HSC population
can express any of the following combination of cell surface
markers characteristic of HSCs: Thy-1 10 Sea-l+ Lineagec-kit+; or CD150+ CD48- Sea-l+ Lineage- c-kit+; or Thy-1 10
CD150+ CD48- Sea-l+ Lineage- c-kit+.
The first HSC population can be obtained from a biopsy
removed from a donor employing techniques known by persons skilled in the art, including the removal of stem cells
from the bone marrow of a donor from large bone masses
utilizing a large needle intended for bone marrow harvesting.
The amount of hematopoietic stem cells needed as the first
HSC population for the present method is less than the
amount ofhematopoietic stem cells needed for a conventional
bone marrow transplantation that may require hundreds of
needle insertions to obtain sufficient material for direct transplantation into a recipient host. Alternatively, HSCs may be
collected by apheresis, a process in which a donor's peripheral blood is withdrawn through a sterile needle and passed
through a device that removes white blood cells, and that
returns the red blood cells to the donor. The peripheral stem
cell yield can be increased with daily subcutaneous injections
of granulocyte-colony stimulating factor. The HSCs are pref-
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to the antagonist, and that have been expanded can be infused
intravenously into the blood stream of the recipient host. The
antagonist-exposed and pre-expanded HSC population can
localize within local niches of a bone marrow after a brief
circulation in the blood stream. The antagonist-induced and
pre-expanded HSC population may be able to respond to
various growth factors produced by endothelial cells within
the local bone marrow niches that may contribute to further
proliferation and/or suppression of apoptosis of the antagonist-exposed and pre-expanded HSC population. Reconstitution of HSCs within the recipient host is achieved when the
total number ofHSCs within the recipient host is at least 25%
greater than before transplantation of the antagonist-induced
and pre-expanded HSC population.
In one embodiment, the donor is the same organism as the
recipient host in that the donor has identical HLA haplotype
as the recipient host, and wherein the recipient host is reconstituted with autologous HSCs when provided with the second HSC population. For example, allogenic bone marrow
transplantation involves two persons, a (non-diseased) donor
and a (diseased) patient-recipient. In autologous transplantion, the risks for developing graft rejection, infection, and
Graft Verses Host Disease ("GVHD") are reduced.
In another embodiment, the donor is not the same organism
as the recipient host, and the donor has a HLA haplotype of
sufficient similarity to the HLA haplotype of the recipient
host, and wherein the recipient host is reconstituted with
allogenic HSCs when provided with the second HSC population. For optimal results, the allogeneic HSC donors should
have identical human leukocyte antigens ("HLA") as the
recipient host, and the recipient host should receive immunosuppressive medications. For example, an allogenic transplant donor may be a relative (e.g., a sibling) or an unrelated
volunteer.
B. In Vivo Methods
Various embodiments provide methods for reconstituting a
recipient host with a population of hematopoietic stem cells
(HSCs) generated in vivo in which the method comprises
administering to the recipient host a pharmaceutical composition comprising an antagonist that reduces latexin expression and/or latexin activity.
The present methods enable clinicians to promote HSC
proliferation within the bone marrow of patients affected by
any type of disorder, disease, or cancer that may reduce the
supply of endogenous HSCs to less than an optimal number.
The recipient host is affected with a disease of the blood, a
disease of the bone marrow, a cancer of the blood, and a
cancer of the bone marrow, an immunological disorder, anemia, leukemia, thalassemia major, sickle-cell disease, myelodysplastic syndrome, lymphoma, aplastic anemia, and/or
multiple myeloma.
The pharmaceutical composition comprises a therapeutically effective amount of the antagonist. The pharmaceutical
composition further comprises a pharmaceutical excipient
known by persons skilled in the art. Pharmaceutical formulations for effective delivery of pharmaceutical composition
will vary depending on the latexin antagonist and mode of
administration. Suitable pharmaceutical carriers are known
by persons skilled in the art (Remington's Pharmaceutical
Sciences (1989), which is incorporated in entirety). Pharmaceutical compositions can be administered by various methods, including by injection, oral administration, inhalation,
transdermal application, or rectal administration. For oral
administration, suitable formulations containing a pharmaceutical compound and pharmaceutically-compatible carriers can be delivered in various forms, such as tablets or
capsules, liquid solutions, suspensions, emulsions, and the

like. For inhalation, suitable formulations containing a pharmaceutical compound and pharmaceutically-compatible carriers can be delivered as aerosol formulations that can be
placed into pressurized propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. For parenteral
administration, suitable formulations containing a pharmaceutical compound and pharmaceutically-compatible carriers can be delivered by intra-articular, intra-venous, intramuscular, intra-dermal, intra-peritoneal, and sub-cutaneous
routes.
Pharmaceutical compositions suitable for use include
compositions containing active ingredients in an effective
amount to achieve its intended purpose. More specifically, a
therapeutically-effective amount means an amount effective
to promote the proliferation ofHSCs and/or inhibit apoptosis
of HSCs in subjects exposed to the present pharmaceutical
compositions. Determination of the effective amounts is well
within the capability of persons skilled in the art. A dose can
be formulated in animal models to achieve a circulating concentration range that includes IC50 value, defined as a dose in
which 50% of cells of a culture show an effect due to the test
compound. Such information can be used to more accurately
determine useful doses in human subjects.
Toxicity and therapeutic efficacy of such compounds can
be determined by standard pharmaceutical procedures utilizing cell cultures or experimental animals in order to determine a LD50 value, the dose determined to be lethal to 50%
of the exposed population, and to determine a ED 50 value, the
dose determined to be therapeutically effective in 50% of the
exposed population. A dose ratio between toxic effect and
therapeutic effect is referred to as the "therapeutic index," or
it can be expressed as the ratio of the LD50 value over the
ED 50 value. Compounds that exhibit high therapeutic indices
are preferred. The data obtained from cell culture assays and
animal studies can be used in formulating a range of effective
dosage for human usage. Optimal dosage range includes a
ED 50 dose with minimal toxicity, although the dosage may
vary within this range depending on a given pharmaceutical
formulation and route of administration. Dosage administered to a subject should be adjusted according to the age of
the subject, the weight of the subject, the manner of administration, and other circumstances unique to each subject.
C. Exemplary Antagonists that Inhibit the Expression and/or
Activity of Latexin and Latexin I so forms/Variants
A HSC population obtained from a donor can be induced to
proliferate ex vivo under in vitro conditions, or an endogenous HSC population within a patient can be induced to
proliferate in situ by exposing the HSC population of interest
to various antagonists that can inhibit latexin gene expression
and/or latexin activity.
Suitable compositions that can inhibit the expression and/
or the activity of latexin and latexin variants include
sequence-specific polynucleotides that can interfere with the
transcription of endogenous latexin gene; sequence-specific
polynucleotides that can interfere with the translation of
latexin mRNA transcripts (e.g., siRNAs, ribozymes);
sequence-specific polypeptides that can interfere with the
protein stability of latexin, the enzymatic activity of latexin,
and/or the binding activity of latexin with respect to substrates and/or regulatory proteins; antibodies that exhibit
specificity for latexin; and small molecule compounds that
can interfere with the protein stability of latexin, the enzymatic activity oflatexin, and/or the binding activity oflatexin.
An effective antagonist can promote HSC proliferation by at
least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%,
70%,75%, 80%, 85%, 90%,95%, or 100%.

10

15

20

25

30

35

40

45

50

55

60

65

US 9,284,530 B2
11

12

1. Sequence-Specific Compounds
a. RNAi Compounds
In one embodiment, various siRNAs that are complementary to human latexin mRNA and mammalian orthologs can
be employed by persons skilled in the art to promote HSC
proliferation and/or inhibit HSC apoptosis. By introducing
such RNAi compounds to a recipient patient deficient in
HSCs, the silencing or inactivation effect of RNAi compounds on latexin gene/gene products within the HSCs can
promote HSC proliferation and/or inhibit HSC apoptosis.
Because introduction of double-stranded RNA ("dsRNA")
that are longer than 30 nucleotides into mammalian cells
induces a sequence-nonspecific interferon response, alternative methods for delivery of interfering RNA molecules
("RNAi") may be suitable. For example, most common form
of RNAi molecules are short-interfering RNAs ("siRNAs")
of 21-23 base-pairs that are chemically or enzymatically synthesized, which can be introduced into mammalian host cells
by various methods, including transfections. However, unlike
fungi, plants, and worms that can replicate siRNAs in vivo,
transfection of siRNA produces only transient gene-silencing
effect in mammalian cells. As an alternative, DNA vectors
encoding precursor-like forms of siRNAs may be used for
stable production of siRNAs in vivo in various hosts, including mammalian cells.
In another embodiment, compounds that can promote HSC
proliferation and/or inhibit HSC apoptosis are contemplated,
in which the compounds comprise an oligonucleotide that can
interact with endogenous messenger RNA encoded by latexin
gene or by latexin isoforms having at least about 70%, 7 5%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence
similarity to SEQ ID NO: 1 (i.e., a sense-strand of human
latexin eDNA). Such RNA oligonucleotide compounds can
be single-stranded or double-stranded. Suitable lengths of
RNA oligonucleotides include molecules containing 15-20
nucleotides, 20-30 nucleotides, 30-50 nucleotides, 50-75
nucleotides, 75-100 nucleotides, 100-150 nucleotides, 150200 nucleotides, and 200-300 nucleotides. In another
embodiment, the present invention is directed to compounds
that can promote HSC proliferation and/or inhibit HSC apoptosis, the compounds include an anti-sense strand that can
hybridize to an endogenously produced messenger RNA, and
that can inhibit the translation of the messenger RNA.
Selection of efficient siRNAs is an empirical process, but
certain rules governing optimal selection of siRNAs are
known. The sequence selected for a siRNA appears to be
critical. For example, siRNAs containing sequence motifs,
such as AAN 19 TT, NAN 19 NN, NARN 17YNN, and
NANN 17YNN, are effective, in which N is any nucleotide, R
is a purine, and Y is a pyrimidine. In addition, regions of
complementary DNA should have non-repetitive sequences,
and should avoid intronic sequences. Suitable siRNAs contain approximately 30-70% GC content, contain even representation of all nucleotides on the anti-sense strand, and do
not contain stretches of single nucleotide, especially stretches
of Gs. Designing suitable SiRNA molecules is within the
scope of persons skilled in the art. The following references
are herein incorporated by reference in their entirety: Henschel et. a!., Nucleic Acids Research, Vol. 32: 113-120
(2004); Naito eta!., Nucleic Acids Research, Vol. 32: 124-129
(2004); Dorsett et a!., Vol. 3: 318-329 (2004); and Brummelkamp et a!., Nature Reviews, Vol. 3: 781-789 (2003);
Pusch eta!., Nucleic Acid Research, 31: 6444-6449 (2003);
and Chiu eta!., RNA 9: 1034-1048 (2003).
Although any region of mRNA can be theoretically targeted, certain sequences that are known binding sites for
mRNA-binding proteins should be avoided, including

untranslated regions, such as the" 5'UTR" and "3 'UTR," startcodons, and exon-exon boundaries. For some mRNA targets,
siRNA -directed silencing may be more effective if the siRNA
sequence is selected at least 50-100 nucleotides downstream
of a start codon, and preferably directed towards the 3' end of
a target mRNA. In addition, the conformation of a mRNA
recognition site within an mRNA target is preferably RNAseH-sensitive, and preferably not within a highly-structured
RNA region. These guidelines are generally applicable since
the choice of a siRNA depends on the target mRNA sequence,
and persons skilled in the art would need to synthesize several
siRNAs to validate the efficiency of each. The specificity of a
siRNA for a single gene can be ascertained by performing a
multiple-genome-sequence alignment, such as a BLAST
search of the selected sequence against sequence databases,
including "Unigene" libraries associated with National Center for Biotechnology Information (NCBI). Potential off-target silencing by siRNA may be minimized by choosing a
siRNA sequence with maximum sequence divergence from a
list of genes with partial-sequence identity to the intended
mRNA target. General principles for siRNA selection are
taught by the following two review articles, which are incorporated by reference (Dorsett and Tuschl, Nature Reviews
Vol. 3: 318-329, (2004); Dykxhoorn eta!., Nature Reviews
Vol. 4: 457-467 (2003)).
Various expression vectors can be constructed to enable
stable production of siRNA-like molecules in vivo. For
example, RNA-pol II promoters may be operably-linked to a
hairpin precursor of a siRNA sequence of interest. RNA-pol
II promoters represent a broad range of promoters that enable
substantial control over parameters governing RNA expression, such as inducible, constitutive, tissue-specific, or developmentally-regulated RNA expression. Alternatively, RNApol III promoters may be used to produce short RNA species
that do not activate the interferon pathway. Suitable RNA-pol
III promoters include class III promoters that lack essential
transcriptional elements downstream of a transcription initiation site, such as U6 and H1 promoters, which may be operably-linked to a siRNA-encoding sequence.
Long-hairpin RNAs, imperfect shRNAs, miRNAs, and
siRNAs, can be designed as follows. For example, a subsequence of a messenger RNA encoded by latexin gene or by
latexin isoforms having at least about 70%, 75%, 80%, 85%,
90%, 95%, 96%, 97%, 98%, or 99% sequence similarity to
SEQ ID N0:1 (i.e., a sense-strand ofhuman latexin eDNA),
can be targeted. For example, an anti-sense strand of shRNA
can be designed by selecting a sub-sequence portion of a
RNA sequence complementary to endogenous latexin messenger RNA and latexin isoforms having at least about 70%
sequence similarity to SEQ ID NO: 1
For designing shRNA, the composition and size of the loop
and length of the stem of a hairpin duplex should be considered. Suitable stem lengths for efficient silencing include a
broad range, including stem lengths of 19-29 nucleotides.
Suitable loop lengths for efficient silencing include a broad
range, including loop lengths of 4-23 nucleotides. In certain
context, hairpin structures with duplexed regions that are
longer than 21 nucleotides may promote effective siRNAdirected silencing, regardless ofloop sequence and length.
Various gene-delivery vectors that are practiced by persons
skilled in the art can be used to introduce the present expression vectors. Examples of viral vectors that may be used to
infect HSC cells include: improved adenoviral vectors (Reynold eta!., Nature Biotechnology 19: 838-842 (2001 )); genedeleted adenovirus-transposon vectors (Yant et a!., Nature
Biotechnology 20: 999-1005 (2002)); recombinant adenoviruses (Bilang-Bleuel eta!., Proc. Nat!. Acad. Sci. U.S.A. 94:
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8818-8823 (1997)); the Moloney-murine-leukemia-virus
("Mo-MuLV") based retroviral vectors (Auten eta!., Human
Gene Therapy 10: 1389-99 (2003)); and poliovirus-repliconbased vectors (Bledsoe eta!., Nature Biotechnology 18: 964969 (2000)). Examples of other suitable viral vectors include:
herpes virus, mumps virus, Sindbis virus, vaccinia virus, such
as the canary pox virus, and lentivirus. The usage of viral
vectors is well known by persons skilled in the art, and for
gene therapy uses, viral infection is preferred generally. The
following references are incorporated by reference in their
entirety: Rob bins and Ghizzani, Mol. Med. Today 1:41 0-41 7
(1995); Robin eta!., Stem Cells 20:514-521 (2002); Chen et
a!., Immunity 19:525-533 (2003); North eta!., Immunity 16:
661-672 (2002); Zhou eta!., Nature Medicine 7: 1028-1034
(2001 ); Ivanova eta!., 298: 601-604 (2002); and Santos et. a!.,
Science 298: 597-600 (2002).
b. Chemically Modified Anti-Sense Oligodeoxyribonucleic
Acids ("ODNs")
In one embodiment, various oligodeoxyribonucleic acid
(ODN) molecules that are complementary to endogenous
messenger RNA encoded by latexin gene or by latexin isoformshavingatleastabout70%, 75%,80%,85%,90%,95%,
96%, 97%, 98%, or 99% sequence similarity to SEQ ID NO: 1
(i.e., a sense-strand of human latexin eDNA), can be
employed by persons skilled in the art to promote HSC proliferation and/or to inhibit HSC apoptosis. By introducing
such oligodeoxyribonucleic acid (ODN) molecules to a
recipient patient deficient in HSCs, the silencing or inactivation effect of RNAi compounds on latexin gene/gene products within the HSCs can promote HSC proliferation and/or
inhibit HSC apoptosis. Suitable oligodeoxyribonucleic acid
molecules ("ODNs") are short polynucleotides of approximately 20 nucleotides in length, that can hybridize with premRNA and mRNA to form RNA-DNA duplexes, which are
degraded by ribonuclease H ("RNase H"). Such ODNs can be
chemically modified to prevent the action of RNase H, to
inhibit translation of mRNA by steric hindrance, to inhibit
splicing of pre-mRNAs, and to inhibit transcription by the
formation of triple helices. Kurreck, J. eta!., Eur. J. Biochem.,
270:1628-1644 (2003); Baker et a!., J. Bioi. Chern., 272:
11994-2000 (1997); Lu, Q. L. eta!, Nature Med., 9:10091014 (2003); and Uil, eta!., Nucleic Acids Res., 31:60646078 (2003) are incorporated by reference in their entirety.
c. Ribozymes
In one embodiment, various ribozymes containing
sequences that are complementary to endogenous messenger
RNA encoded by latexin gene or by latexin isoforms having at
least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%,
98%, or 99% sequence similarity to SEQ ID NO: 1 (i.e., a
sense-strand of human latexin eDNA), can be employed by
persons skilled in the art in order to reduce latexin expression
and/or latexin activity that results in HSC proliferation and/or
HSC apoptosis. Ribozymes, including the "hammer-head"
ribozyme, are RNA molecules that bind target mRNA by
assuming a unique secondary structure when hybridized to
target mRNA, which enables catalytic hydrolysis of a phosphodiester bond within in the backbone of target mRNA.
Efficient cleavage by a ribozyme requires the presence of
divalent ions, such as magnesium, and is also dependent on
target RNA structure, and relative proximity between
ribozyme and target molecule. RNA-localization signals or
RNA chaperones may be used so that low concentrations of
ribozymes are sufficiently effective in silencing latexin and
latexin isoforms. Ribozymes can be chemically synthesized
in vitro, and can be transcribed from expression vectors in
vivo. Methods for ribozyme construction and utilization are
known by persons skilled in the art. Doudna and Cech,

Nature, 418:222-228 (2002); Kuwahara eta!, J. Biochem.,
132:149-155 (2002); Michienzi and Rossi, Methods Enzymol., 341:581-596 (2001); and Good eta!., Gene Ther. 4:4554, (1997) are herein incorporated by reference.
d. Other Compounds
In another embodiment, suitable antagonists include compounds that can interact with polypeptides having at least
about70%, 75%,80%,85%,90%,95%,96%,97%, 98%,or
99% sequence similarity to SEQ ID N0:2, that can inhibit the
activity of the bound polypeptide, and that can promote the
proliferation ofHSCs and/or suppress the apoptosis ofHSCs.
In addition, compounds that can interact with genomic DNA
containing exons having at least about 70%, 75%, 80%, 85%,
90%, 95%, 96%, 97%, 98%, or 99% sequence similarity to
SEQ ID N0:1 (i.e., a sense-strand of human latexin eDNA)
can be employed. In addition, compounds that can interact
with RNA transcripts encoded by a gene, in which the exon
sequences have at least about 70%, 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98%, or 99% sequence similarity to SEQ ID
N0:1 (i.e., a sense-strand of human latexin eDNA) can be
employed. Various compounds that can inhibit the expression
and/or activity of latexin or latexin isoforms can be either
naturally-occurring or synthetically-produced. Large combinatorial libraries of chemical/biological compounds can be
generated by various chemical and biological synthesis methods known in the art. Such combinatorial chemical libraries
include: small organic molecule libraries (benzodiazepines,
Baum C&EN, Jan. 18, page 33 (1993)); Chen eta!., J. Amer.
Chern. Soc. 116:2661 (1994)), such as isoprenoids (U.S. Pat.
No. 5,569,588), thiazolidinones and metathiazanones (U.S.
Pat. No. 5,549,974), pyrrolidines (U.S. Pat. Nos. 5,525,735
and5,519,134),morpholino compounds (U.S. Pat. No. 5,506,
337), and benzodiazepines (U.S. Pat. No. 5,288,514), oligocarbamates (Cho eta!., Science 261:1303 (1993)), and peptidy! phosphonates (Campbell et a!., J. Org. Chern. 59:658
(1994)). Exemplary combinatorial libraries include: various
peptide libraries (U.S. Pat. No. 5,010,175; Furka, Int. J. Pept.
Prot. Res. 37:487-493 (1991); Houghton eta!., Nature 354:
84-88 (1991)); peptoid libraries (PCT Publication No. WO
91/19735); encoded peptides (PCT Publication No. WO
93/20242); random bio-oligomers (PCT Publication No. WO
92/00091); benzodiazepines (U.S. Pat. No. 5,288,514); diversomers such as hydantoins, benzodiazepines and dipeptides
(Hobbs et a!., Proc. Nat. Acad. Sci. USA 90:6909-6913
(1993)); vinylogous polypeptides (Hagihara eta!., J. Amer.
Chern. Soc. 114:6568 (1992)); nonpeptidal peptidomimetics
with glucose scaffolding (Hirschmann eta!., J. Amer. Chern.
Soc. 114:9217-9218 (1992)); various nucleic-acid libraries;
various peptide-nucleic acid libraries (U.S. Pat. No. 5,539,
083); various carbohydrate libraries (Liang et a!., Science,
274:1520-1522 (1996); U.S. Pat. No. 5,593,853)); and various antibody libraries (Vaughn eta!., Nature Biotechnology,
14(3):309-314 (1996)).
D. Identification ofFunctionally-Related Isoforms ofLatexin
The present methods and compositions can be employed
for targeting variants of latexin that have similar properties/
activities within HSCs of many types of mammalian subjects.
Functionally-related isoforms oflatexin can be identified by
searching various genomic databases and conducting multigenome-wide sequence alignments in order to identifY
homologous sequences of interest. Related orthologous
sequences can be identified by searching composite genomic
databases. The breath of a database search is limited by the
scope of representative model organisms for which sequence
data is available.
Homology can be determined by various methods, including alignments of open-reading-frames ("ORFs") contained
in private and/or public databases.Any suitable mathematical
algorithm may be used to determine percent identities and
percent similarities between any two sequences being com-
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pared. For example, nucleic acid and protein sequences of the
present invention can be used as a "query sequence" to perform a search against sequences deposited within various
public databases to identify other family members or evolutionarily-related sequences. Genomic sequences for various
organisms are currently available, including fungi, such as the
budding yeast, or Saccharomyces cerevisiae; invertebrates,
such as Caenorhabditis elegans and Drosophila melangaster;
and mammals, such as the mouse, rat, and human. Exemplary
databases for identifYing orthologs of interest include
Genebank, Swiss Protein, EMBL, and National Center for
Biotechnology Information ("NCBI"), and many others
known in the art. These databases enable a user to set various
parameters for a hypothetical search according to the user's
preference, or to utilize default settings. Tables 1-3, provided
below, lists the accession numbers and gene identification
numbers for exemplary mammalian orthologs. Suitable
latexin variant that may be targeted for suppression or inhibition include the carboxypeptidase inhibitor (CARIN)
described in U.S. Pat. No. 5,998,373.

TABLE !-continued
Gene Bank Accession Nwnber for Exemplary Mouse,

Human, and Rat Latexin mRNA.

10

Organism

Accession Number

Gene IDS

Rattus norvegicus

NM-031655

14269567

NM-020169

21359932

(Rat)
Homo Sapiens

(human)
15

TABLE2
Gene Bank Accession Nwnber for Exemplary Mouse,
Hwnan and Rat Latexin Protein.

20

TABLE 1
Gene Bank Accession Number for Exemplary Mouse,

Human and Rat Latexin mRNA.
Organism

Accession Number

Gene IDS

Mus musulus
(Mouse)

NM-016753

31980631

25

Organism

Accession Number

Gene IDS

Mus musulus
(Mouse)
Rattus norvegicus
(Rat)
Homo Sapiens
(human)

NP-058033

31980632

NP-113843

14269568

NP-064554

21359933

TABLE3
Mammalian Homologs for Latexin

Accession
Number

Percentage

Gene IDS

Identity

Mus musulus AK032170.1
(Mouse)

26327996

99.91

Mus musulus AK149981.1
(Mouse)

74211713

100.00

1669620

99.50

AC124190.4

23499687

100.00

AC124190.4

23499687

100.00

AC124190.4

23499687

100.00

AC124190.4

23499687

100.00

AC124190.4

23499687

100.00

AC124190.4

23499687

100.00

AK018305.1

12857946

99.58

Organism

Mus musulus D88769.1
(Mouse)
Mus musulus
(Mouse)
Mus musulus
(Mouse)
Mus musulus
(Mouse)
Mus musulus
(Mouse)
Mus musulus
(Mouse)
Mus musulus
(Mouse)
Mus musulus
(Mouse)

Gene Information
Mus musculus adult
male olfactory brain
eDNA, RIKEN fulllength enriched library,
clone: 6430407E02
product: Latexin, full
insert sequence
Mus musculus bone
marrow macrophage
eDNA, RIKEN fulllength enriched library,
clone: G530111019
product: Latexin, full
insert sequence
Mus musculus mRNA
for Latexin, complete
cds
Mus musculus BAC
clone RP23-267M9
from 3, complete
sequence

Mus musculus 10 days
neonate cerebellum

eDNA, RIKEN fulllength enriched library,
clone: 6530401A10
product: Latexin, full
insert sequence

US 9,284,530 B2
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TABLE 3-continued
Mammalian Homologs for Latexin

Organism

Accession
Number

Gene IDS

Percentage
Identity Gene Information

Mus musulus AK198791.1
(Mouse)

56022968

100.00

Mus musulus AK187030.1
(Mouse)

56011207

99.52

Y18435.2

6066618

94.33

Y18435.2

6066618

96.92

Rattus
norvegicus
(Rat)
Rattus
norvegicus
(Rat)

EXAMPLES

Mus musculus eDNA,
clone: Y1 G0129D08,
strand: minus,
reference: ENSEMBL:
Mouse-TranscriptENST: ENSMUST00000058981,
based on
BLAT search
Mus musculus eDNA,
clone: YOG0139J09,
strand: minus,
reference: ENSEMBL:
Mouse-TranscriptENST: ENSMUST00000058981,
based on
BLAT search
Rattus norvegicus
Latexin gene, exons 1
to 6

age is indicated with the dashed bar. Data were analyzed by
either student t-test by assuming unequal variance with
The following examples are offered by way of illustration
p<0.05 (two-tail or one-tail as indicated), or by one-way
and not by way of limitation. Examples 1 provides a map of 30 ANOVA.
The Chr 3 congenic mice were generated by well-estabcongenic intervals defined in the reciprocal strains. Example
lished methods known in the art. Mouse strains congenic for
2 provides an in vitro method for determining HSC frequenthe Chr 3 QTL were generated by crossing the genomic
cies by cobblestone area-forming cell (CAFC) assay.
interval harboring the QTL using D2, as the donor strain, and
Example 3 provides an in vivo method for determining HSC
frequencies by a competitive limiting-dilution assay. 35 B6, as the recipient strain (symbolized as B.D Chr3), and vice
versa (D.B Chr3). The two reciprocal congenic strains were
Example 4 provides the identification oflatexin by a genomederived by a 'speed congenic' approach involving at least
wide linkage analysis that correlates three QTL with HSC
eight backcrosses with the respective background strains.
population size. Example 5 provides data that validates the
Both congenic lines were homozygous within their respective
linkage analysis and heritability of latexin. Example 6 provides the effect of latexin on HSC Replication. Example 7 40 congenic intervals and genotyped exclusively for background
strain alleles using 100 microsatellite markers scattered
provides the effect oflatexin on HSC Self-renewal. Example
throughout the non-congenic genome. Congenic mice were
8 provides the effect of latexin expression on apoptosis.
genotyped every 6 months through genetic marker-based
Example 9 provides microarray analysis of LSK cells.
polymerase chain reaction. All primers for simple sequence
Example 10 provides Lxn mRNA levels in hematopoietic
cells. Example 11 provides Lxn expression in undifferenti- 45 repeat (SSR) element markers were bought from Research
Genetics (Huntsville, Ala.). Two strains of Chr 3 congenic
ated and differentiated hematopoietic cell populations.
Example 12 provides Lxn protein levels in hematopoietic
mice were generated and maintained: B.D Chr3 (14 cM-33
cells of congenic and background strain mice. Example 13
eM) congenics with D2 QTL being introgressed onto the B6
background, and their reciprocal congenic strains D.B Chr3
provides Cis-Regulation ofLxn expression. Example 14 provides a decrease in stem cell numbers by the overexpression so (19 cM-60 eM) with B6 QTL on a D2 background. B6.SJL
(Ptprc 6 [CD 45.1]) mice from Charles River laboratories (FreofLxn.
derick, Md.) were used as transplantation recipients in comExample 1
petitive repopulation experiments. Female mice (6 to 10
weeks old) were housed in the animal facilities of the UniMapping Congenic Intervals Containing Latexin
55 versity of Kentucky under pathogen-free conditions according to NIH-mandated guidelines for animal welfare. They
FIG. 2 illustrates a genomic map of congenic intervals
were fed with acidified water and food ad libitum.
identified in reciprocal Chr.3 congenic mouse strains. The
congenic interval, mutually inclusive in the two reciprocal
Example 2
strains, spans from 36.5 megabase (Mb) (19.2 centiMogan 60
Determination of HSC Frequencies by In Vitro
(eM)) to 67 Mb (33 eM), and the location of the marker
(D3Mit5) most tightly linked to the trait is localized within
Cobblestone Area-Forming Cell (CAFC) Assay
50.4 Mb (25 eM). The C57BL/6 ("B6") (Ptprc 6 [CD 45.2])
and DBA/2 ("D2") mice were background strains and purTo quantifY primitive hematopoietic cells derived from
chased from the Jackson Laboratories (Bar Harbor, Me.). The 65 bone marrow in B6, D2, and 26 BXD RI strains, an in vitro
cobblestone area-forming cell (CAFC) assay was performed.
total length of Chr3 (-160 Mb) is indicated on the top.
Genomic interval with 95% of confidence limits of the linkIn this assay, each cobblestone area represents a population
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formed by clonal amplification of a single stem cell or a
progenitor cell, and distinct populations arise in a chronological continuum. For determining the relative chronological
age of a hematopoietic cell, the latency period is determined
by measuring the duration before clonal expansion by a
primitive hematopoietic cell. A longer latency period indicates a more primitive hematopoietic cell. Cobblestone areas
were counted after 35 days of culture, a late time-point. Primitive hematopoietic cells measured at this time-point correlate
strongly with long-term repopulating stem cells in vivo.
Whole bone marrow cells and sorted LSK cells, described
below in Example 5 and FIGS. 4A-4B, were evaluated in a
cobblestone area-forming cell (CAFC) assay. In brief, a confluent monolayer ofFBMD-1 stromal cells was established in
96-well tissue culture-treated plates (Costar, Cambridge,
Mass.). After 7 to 10 days, wells were seeded either with
unfractionated marrow at a dose of 81,000, 27,000, 9,000,
3,000, 1,000, or 333 cells per well, or with sorted LSK cells at
a dose ofl, 3, 10, or 30 cells per well using an automated cell
deposition unit. Twenty or 60 replicate wells per cell number
were evaluated in experiments with unfractioned or sorted
cells, respectively. The cells were cultured in Iscove's Modified Dulbecco Medium (IMDM), containing 20% horse
serum, 80 U/mL penicillin, 80 mg/mL streptomycin (all from
Life Technologies), 10-4 ~-mecaptoethanol, and 10- 5 M
hydrocortisone (both Sigma, St. Louis, Mo.). Individual wells
were screened at day 7, 14, 21, 28 and 35 for the presence of
a cobblestone area, defined as a colony of at least 5 small,
non-refractile cells growing underneath the stroma. A longer
latency period before the appearance of cobblestones correlates with a more primitive state of the stem cell. Thus, the
most primitive HSCs show cobblestones at day 35, whereas
colonies that appear earlier are derived from more committed
progenitor cells (HPCs ). Frequencies of CAFCs were calculated by using maximum likelihood analysis and are equal to
1 divided by the number of cells yielding 3 7% negative wells.
The frequencies of CAFC day35 in BXD RI mouse strains
were measured, and were used to perform genome-wide
searches for linked loci within a GeneNetwork database.

by hypotonic lysis using NH4 Cl. The leukocytes were stained
in triplicate with fluorescein isothiocyanate (FITC)-conjugated anti-CD45.2 monoclonal antibody (mAb) (clone
ALI4A2) and phycoerythrin (PE)-conjugatedmAbs (BectonDickinson-PharMingen, San Diego, Calif.) specific for either
B (anti-CD45R/B220; clone RA3-6B2) or T lymphocytes
(anti-Thy-1.2; clone 30H12), or granulocytes (anti-Ly6G/Gr1; clone RB6-8C5), and macrophages (anti-CD11 b/Mac-1;
clone M1/70). Samples were analyzed using a FACScan
instrument (Becton-Dickinson Immunocytometry Systems,
San Jose, Calif.). The frequencies of long-term HSCs were
calculated from the proportions of negative recipients in each
cell dose group by using L-Calc software (StemCell Technologies Inc., Vancouver, BC). In each cell dose group, <5%
of the circulating B, T, and myeloid cells were regenerated
from CD45.2 stem cells. The results obtained from two independent experiments showing the effect of D2 alleles on the
number of long-term repopulating HSCs in B.D Chr3 mice
are provided below in FIG. 4C in Example 5.
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In Vivo Determination of HSC Frequencies in
Rodents by Competitive Limiting-Dilution Assay
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A limiting-dilution analysis in competitively repopulated
host animals was performed over a long term (20 week)
period in order to functionally identifY and to quantifY HSCs
in vivo. Graded numbers ofbone marrow cells from B.D Chr3
congenic or B6 mice were first admixed with a fixed dose of
competitor cells, and were transplanted into groups of
lethally-irradiated mice. Lymphomyeloid reconstitution by
either B.D Chr3 or B6-derived cells was assessed in the
peripheral blood cells 20 weeks after transplantation. In limiting-dilution competitive repopulation assay, graded numbers (6,000; 20,000; and 60,000) ofB.D Chr3 congenic or B6
"test" cells (CD45.2) were admixed with a radio-protective
dose (2x10 5 ) of competitor cells (CD45.1), and were injected
intravenously into lethally irradiated (900 Gy) CD45 .1 recipientmice.
Recipients were bled from the retro-orbital sinus 20 weeks
after transplantation. Peripheral blood cell counts were performed on anesthetized mice bled from the retro-orbital
venous plexus. Circulating leukocyte, erythrocyte, and platelet counts were measured by analysis of 40 ul blood using a
System 9118+ Hematology Series Cell Counter (Biochem
Immunosystems, Allentown, Pa. Erythrocytes were depleted

FIG. 3 illustrates a genome-wide linkage analysis based on
GeneNetwork that associates the trait regulating HSC population size with three quantitative trait loci (QTL) on Chromosomes (Chr) 3, 5, and 18, respectively. In FIG. 3, these
QTLs linked genetically to the trait ofHSC population regulation at a 'suggestive' statistical level of association, in which
the likelihood ratio statistic (LRS) values (solid blue line) for
the corresponding markers (D3Mit5, D5Mit352, D18Mit53)
are located between the suggestive threshold (dashed green
line) and the significant threshold (dashed blue line). The 19
autosomes and Chr X of the mouse genome are labeled across
the top, and some of micro satellite markers are listed across
the bottom. The positive additive regression coefficient (solid
red line) for each QTL indicates that D2 alleles increase the
trait and that the B6 alleles decrease the trait. The positive
additive regression coefficient for each QTL indicates that the
D2 alleles have a positive effect on HSC population size and
that the B6 alleles have a negative effect on HSC population
Example 5
Validation of the Linkage Analysis and Heritability
ofLatexin

50

55
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To validate the results from genome-wide linkage analysis
described in Example 4, CAFC day 35 assays were performed
on whole bone marrow cells and LSK cells. FIG. 4A illustrates the CAFC day 35 frequency observed for femur cells
(whole bone marrow cells derived from reciprocal congenic
strains) of Chr3 congenic mice when compared to background mice. In FIG. 4A, introgression ofD2 alleles onto the
B6 background in the QTL region caused nearly a 2-fold
increase in CAFC day35 number (P=0.003) representing the
number of HSCs in B.D Chr3 congenic mice, whereas the
introgression of B6 alleles onto the D2 background caused
more than a 50% decrease (P=0.02). The values are shown as
mean±SEM (n>9). The absolute number of CAFC day35 per
femur (±SEM) for all strains as follows: B66: 397±59; B.D
Chr3: 724±73; D2: 1978±684; D.B Chr3; 1532±286. Moreover, numbers for CAFC day 7 and day 21, which represent
hematopoietic progenitor cells (HPCs) at different stages, and
the cell counts for peripheral blood leukocytes, erythrocytes,
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and platelets showed no differences among congenic and
background strains. This suggested that the Chr 3 QTL specifically regulates HSC population size.
FIG. 4B illustrates the CAFC day 35 frequency observed
for LSK cells of Chr3 congenic mice compared to background mice. The LSK cells represent a highly-enriched
population ofHSCs comprising about 0.03% of total marrow.
In FIG. 4B, similar to results obtained with unfractionated
marrow in FIG. 4A, the D2 alleles significantly increased the
CAFC day35 number when compared to B6 alleles exhibiting
a decreased CAFC day35 number in the LSK population
(P<0.05). The values are shown as mean±SEM (n>9). The
absolute number of CAFC day35 per 100,000 Lin-negative,
Sea-l+, c-kit+ cells (±SEM) for all strains as follows:
B6:1316±172; B.D Chr3: 2000±218; D2: 10000±1010; D.B
Chr3; 7143±721. The LSK cells, were isolated by selecting a
bone marrow population null for cell markers characteristic
of lineage-specific differentiated blood cells (Lin-negative)
and positive for the Sea-l and c-Kit cell markers. This population was sorted using flow cytometry and assayed for CAFC
day 35 numbers in 4 strains.
FIG. 4C illustrates the effect ofD2 alleles on the number of
long-term repopulating HSCs in B.D Chr3 mice. In FIG. 4C,
D2 alleles that introgressed in the region of the Chr 3 QTL
caused a 73% increase in the total number of long-term
repopulating HSCs (P=0.04) in B.D Chr3 mice compared to
B6 mice, as determined from two independent experiments.
Total number of long-term repopulating HSCs (LTRC) B.D
Chr3 congenic and B6 mice is shown, as average per femur
(±SEM). LTRC frequencies were measured by competitive
limiting-dilution analysis described below using femur cells
ofB6 and B.D Chr3 mice. Thus, both qualitatively and quantitatively, these results corroborated the results obtained in
vitro.
A long-term, limiting-dilution analysis in competitively
repopulated animal hosts was performed, as further described
above in Example 3. Graded numbers of bone marrow cells
from B.D Chr3 congenic or B6 mice were admixed with a
fixed dose (2xl 0 5 ) of competitor cells and transplanted into
groups of lethally-irradiated mice irradiated to ablate their
endogenous hematopoietic system. The competitor cells and
recipient mice have a CD45.1 surface marker, whereas B.D
Chr3 and B6 mice carry the CD45.2 marker on virtually all
hematopoietic cells. This genetic marker is not presently
available on the D2 background that also bears CD45.2,
which precludes analogous experiments with the reciprocal
congenic strain. Twenty weeks after transplantation, lymphomyeloid reconstitution by either B.D Chr3 or B6-derived
cells was assessed in the peripheral blood cells 20 weeks after
transplantation for the presence of CD45.2 cells by flow
cytometry.
Together, these three independent studies support the conelusion that a Chr 3 QTL in the congenic intervals confers the
phenotype (HSC population regulation), and confirms the
results obtained by linkage analysis. In the context of these
congenics, the QTL accounts for a significant portion of the
natural variation of this parameter between the progenitor
strains, despite 'suggestive' linkage of the phenotype with
two other QTLs (Chr 5 and ChriS) and with the presence of
several other QTLs that approach 'suggestive' linkage illustrated in FIG. 3.

approaches. First, in vivo BrdU incorporation was used to
determine cells in the S phase of the cell cycle. Mice were
injected intraperitoneally with BrdU (1 mg per kg body
weight) and sacrificed 90 minutes later. Bone marrow LSK
cells were identified as described above. Analysis of BrdU
incorporation in LSK was performed using BrdU Flow Kit
(Pharmingen, San Diego, Calif.) according to the manufacturer's instruction. Second, the fraction of cells killed by a
1-hour in vitro incubation with hydroxyurea (HU) was measured. Hydroxyurea (HU) is an agent that blocks DNA synthesis and stops cell division by inhibiting ribonucleotide
reductase. Briefly, all bone marrow cell suspensions were
diluted to a concentration of lxl0 7 cells in 1 mL. Hydroxyurea (Sigma, StLouis, Mo.; 200 ug/mL, a total volume of 10
ul) was added to one sample, and incubated with the control
sample for 1 hour at 33° C. The standard CAFC assay was
then used to assay both HU-treated and control samples. The
fraction of cells killed by HU was calculated by dividing the
CAFC frequency in the HU-treated sample by the control
value.
FIG. SA illustrates that D2 alleles confer an increase in
HSC replication and that B6 alleles confer a decrease in HSC
replication. The role of Chr 3 QTL in HSC replication, the
proportion of LSK cells in S phase of the cell cycle were
determined by measuring the incorporation of 5-bromodeoxyuridine (BrdU). In agreement with previous data, 4.5%
(± 1.7%) ofB6 LSK cells were labeled with BrdU for one hour
following administration in vivo, whereas more than twice as
many D2 LSK cells were labeled under the same conditions
(11%±2.5%) (P=O.Ol). In FIG. SA, introgressionofD2 alleles significantly increased the BrdU-positive LSK population
(15%±1.4%) (P=O.OOOl) in B.D Chr3 congenic LSK cells, a
proportion similar to that found in D2 cells. As expected, B6
alleles decreased the BrdU incorporation and conferred the
B6 phenotype to D.B Chr3 cells (5.9%±1.2%). Replication of
HSCs measured by BrdU incorporation in animals given a
single pulse ofBrdU. Results present the mean (±1 SD) of the
fraction ofBrdU positive LSK cells (n=S per strain).* indicates the comparison between B6 and D2, and ** indicates
the comparison between congenics and their respective background mice. P values are shown in the figure.
To determine the effect of QTL on cell cycle kinetics, the
CAFC day7 progenitor cells killed by hydroxyurea (HU) in
the reciprocal congenic strains, B6, and D2 mice were measured. FIG. SB illustrates the effect of Chr 3 QTL on the
cell-cycle kinetics of the progeny ofHSCs, also referred to as
hematopoietic progenitor cells (HPCs). Proliferation of
HPCs measured by CAFC day7 cells killed by hydroxyurea
(HU) in reciprocal congenic and B6, D2 strains. Data are
shown as the average (±SD) of 3 independent experiments
(n;;:9). *indicates the comparison between B6 and D2, and**
indicates the comparison between congenics and their respective background mice. P values are shown in the figure. The
results showed that the D2 alleles in and around the Chr 3
QTL in a B6 background quantitatively can reproduce the
higher killing rate observed in D2 mice. Similarly, B6 alleles
on a D2 background reproduced the entire variation in this
trait between B6 and D2 mice. These results underscore the
effect of the Chr 3 QTL on cell-cycle kinetics of HSC and
their immediate progeny. Interestingly, progenitor cell numbers and differential blood cell counts showed no differences
among the congenic and background strains, showing that
compensatory mechanisms during downstream amplification
of differentiating cells obviated the variation in the final cell
outputs in the multiple blood cell lineages.
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The Effect of Latexin Expression on HSC
Replication
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The effect oflatexin expression on the proliferative activity
of various primitive cells was assessed using two independent
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Example 7

the comparison between B6 and D2, and ** indicates the
comparison between congenics and their respective background mice. P values are shown in the figure.
Introgression of D2 alleles around the Chr 3 QTL, in the
B.D Chr3 congenic, resulted in an apoptotic LSK subpopulation (0.6%±0.1 %) similar to that of D2 mice, which suggests that the congenic interval conferred the entire phenotype. Surprisingly, analysis of marrow from the reciprocal
congenic strain revealed a very low (0.3%±0.03%) apoptotic
LSK population. Thus, B6 alleles at and around the QTL do
not confer the B6 phenotype onto D2 HSCs. In fact, apoptosis
was significantly (P=0.02) less than in the D2 background
strain. This result may be due to genes in the mutually exclusive congenic intervals of the reciprocal strains, or genes in
the D2 background having a strong negative effect on HSC
apoptosis. The results suggest that the QTL might act through
a mechanism influencing apoptosis in HSCs.

The Effect of Latexin Expression on HSC
Self-Renewal
5

The self-renewal capacity ofB.D Chr3 congenic HSCs was
tested in serial transplant experiments in which B.D Chr3
congenic HSCs and B6 marrow cells were co-transferred to
recipients so that both types of cells competed for engraftment. In serial bone marrow transplantation, B.D Chr3 congenic or B6 "test" cells were injected into the primary recipients along with equal number of competitor cells (lxl0 6 ).
Sixteen weeks after transplant, marrows were harvested from
the primary recipients, and were transplanted into secondary
recipients. An identical regimen was repeated twice more,
culminating in engrafted quaternary hosts. At each transplant,
the peripheral blood, bone marrow, and bone marrow LSK
cells were analyzed. The competitive advantage and selfrenewal capacities were analyzed by comparing the percentage ofB.D Chr3 congenic-derived or B6-derived cells at each
round of transplantation.
FIG. SC illustrates that D2 alleles of the Chr 3 QTL confer
HSCs with higher self-renewal capability. In FIG. SC, congenic stem cells maintained their competitive advantage at
every round of transplantation in each cell population, demonstrating that they retained the characteristic ability of stem
cells to self-renew and to give rise to normal differentiated
progeny when challenged with replicative stress. Consistent
with the extensive self-renewal ability ofB.D Chr3 stem cells,
all (16) of the quaternary recipients transplanted with congenic cells survived long-term, whereas half (8 of 16) of the
recipients receiving only B6 cells failed to survive to the
10-week evaluation time-point in 4'h generation recipients.
Thus, serial bone marrow transplantation in a competitive
repopulation setting clearly demonstrates that D2 Chr 3 QTL
confers HSCs with higher self-renewal capability, and that
this capacity is intrinsic to the HSCs. B.D Chr3 (dashed line)
or B6-derived (solid line) peripheral blood leukocytes, BM
nucleated and BM LSK cells were analyzed 16 weeks after
they were transplanted into primary (1st), secondary (2nd),
tertiary (3rd) and quaternary (4th) recipients. Each data point
represents the average for groups of mice (n2:l6). The survival rate of quaternary recipients transplanted with either
B.D Chr3 or B6 cells is shown in the last panel.
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Example 9
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Microarray Analysis of LSK Cells to IdentifY
Differentially Expressed genes within Consenses
Congenic Interval
25
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Example 8
The Effect of Latexin Expression on Apoptosis
To determine whether allelic differences in the Chr 3 congenic interval affected steady-state apoptosis in HSC population, apoptosis was assessed by Annexin V-staining ofbone
marrow LSK cells.
FIG. SD illustrates bone marrow LSK cells subject to apoptosis as detected by Annexin V-staining. Top two plots show
the gates to identify Lin-negative, Sea-l+ and c-kit+(LSK)
stem cells. Bottom left plots identify Annexin V +, 7AADnegative apoptotic cells in LSK cells. The plots on the right
are from the thymocyte control for determination of Annexin
V and 7AAD quadrants. Plots are from one representative
animal.
FIG. SE illustrates Aunexin V-stained LSK populations
representing steady-state B6 and D2 bone marrow. In FIG.
SE, a significant variation (P=0.04) in Annexin V-staining in
LSK populations representing steady-state B6 (2.7%±0.4%)
and D2 (0.9%±0.2%) bone marrow was observed. The values
for each strain are the mean (±1 SD) for 8 animals.* indicates
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Oligonucleotide arrays ofLSK cells were performed by the
Microarray Facility Center at the University of Kentucky.
Briefly, total RNA were extracted from at least 550,000 sorted
LSK cells from a minimum of 40 mice using RNeasy® Kit
(QIAGEN, Valencia, Calif.). The extracted RNA was reverse
transcribed into eDNA, which was subsequently used to synthesize biotin-labeled cRNA. The labeled cRNA was then
fragmented and hybridized to the Mouse Genome U74Av2
chips (MGUAv2, Aff)'metrix, Santa Clara, Calif.). The genechips were then washed, stained, and subsequently scam1ed
for quantification of gene expression. Three independent biological samples were obtained for each strain and each was
run on an individual chip. The gene expression levels were
compared among all4 strains using one way-ANOVA with a
statistical cutoff ofP<0.05. The genes that were differentially
expressed were screened for genomic location and function
of the gene products.
Oligonucleotide arrays were utilized to screen for genes in
the consensus congenic interval whose differential expression may account for the observed phenotypic variations.
LSK cells were sorted from bone marrow of the reciprocal
congenic mice, and the two background strains mice. Large
independently sorted biological samples for total RNA
extraction were used to avoid representational skewing oflow
abundance mRNAs that may accompany amplification by
PCR. Triplicate RNA samples, each independently obtained
from at least 550,000 LSK cells sorted and pooled from a
minimum of 40 mice, were collected from the four strains.
Each RNA sample (4 strainsx3 replicates= 12 in all) was
hybridized to an individual microarray chip (MGU Av2
Aff)'metrix). Results obtained from the triplicate chips for
each strain were analyzed using Aff)'metrix Microarray
Suite™ software, and were compared using one-way
ANOVA for each congenic-background strain pair. The number of genes differentially expressed between B.D Chr3 and
B6 strains was 96 (P<0.05) and between D.B Chr3 and D2
strains was 84 (P<0.05). Because congenic intervals represent less than 1% of the entire genome, these numbers are
commensurate with the 940 differentially expressed genes
measured between B6 and D2 LSK cells in these experiments.
Table 4 is a list of genes differentially expressed in reciprocal Chr 3 congenic and B6, D2 HSCs, as shown below. In
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Table 4, only 17 genes on 11 different chromosomes were
mutually inclusive in comparisons between the reciprocal
congenics and their respective background strains. Of 17
differentially expressed genes, the D2 and B6 alleles had
opposite effects on transcription in 9/!7. 'Vl7 were mapped to
Chr 3, but only 1/4 was located in the consensus congenic
interval, near the marker of highest linkage in the mapping
(D3Mit5). The gene was identified to be latexin (Lxn), whose
expression was upregulated by B6 alleles and down-regulated
by D2 alleles, a pattern suggested by the linkage analysis.

ground mice. Results are the average (±1 SD) of 12 measurements derived from 3 independent biological examples.
Example 11
Lxn Expression in Undifferentiated and
Differentiated Hematopoietic Cell Populations
Lxn expression levels were determined along the differentiation pathway in the hematopoietic system. FIG. 6B illustrates quantitation of Lxn transcripts by real-time PCR in

TABLE4
Genes differentially expressed in reciprocal Chr 3 congenic and B6. D2 HSCs.
Chromosomal
location (Mb)

Entrez
gene ID 1. Molecular function

Probe Set

Gene title

Gene symbol

101209 at

Fe receptor, IgE, high affinity I, alpha
polypeptide
Growth factor independent lB
Latexin

Fcerla

1 (173)

14125 Receptor activity; IgE binding

102260 at#
96065 at#

Gfilb
Lxn

2 (28)
3 (67)

92770 at*

SlOO calcium binding protein A6 (calcyclin)

S100a6

3 (91)

98600 at#

SlOO calcium binding protein All
(calizzarin)
RIKEN eDNA 4930577M16 gene
(transmembrane protein 56)
General transcription factor III A
RIKEN eDNA 2610507L03 gene
RIKEN eDNA 9130011J15 gene
Amyloid beta (A4) precursor-like protein 2

SlOOall

3 (93)

14582 ATP binding
17035 Enzyme inhibitor activity
Metalloendopeptidase inhibitor activity
20200 Calcium ion binding; Protein binding
Growth factor activity
20195 Cytokine activity; Calcium ion binding

4930577 M16Rik
(Tmem56)
Gtf3a
2610507L03Rik
9130011J15 Rik
Aplp2

3 (121)

99887 Unknown

5
7
8
9

66596
72140
66818
11804

101026- at*
16128 at#

Pituitary tumor-transforming 1
MYB binding protein (P160) la

Pttgl
Mybbpla

11 (43)
11 (72)

30939
18432

93134- at
100391 at
100343 at*

Neuronal pentraxin 1
Mitogen activated protein kinase 8
Tubulin, alpha 1

Nptxl
Mapk8
Tubal

11 (119)
14 (29)
15 (99)

18164
26419
22142

103282 at*

RAS, guanyl releasing protein 211
similar to calcium and DAG-regulated
guanine nucleotide exchange factor I

Rasgrp211

19 (6)

LOC381240

19395 II
381240

Fatty acid desaturase 1

Fads!

19 (9)

76267

103257 at
94559 102011
94286 93498

at
at
at
s at#

160391 at

(145)
(23)
(71)
(31)

DNA binding
Unknown
Unknown
DNA binding; Protein binding
Serine-type endopeptidase inhibitor
activity
Cysteine protease inhibitor activity
Protein binding Transcriptional repressor
activity
Calcium ion binding
Kinase activity; Transferase activity
GTPase activity; GTP binding
Structural constituent of cytoskeleton
Guanyl-nucleotide exchange factor activity
Calcium ion binding; Diacylglycerol
binding
Kinase activity
Linoleoyl-CoA desaturase activity
Oxidoreductase activity

Total RNA isolated from LSK cells in B.D Chr3, D.B Chr3 congenic, and B6, D2 mice was reverse transcribed into eDNA and subsequently used for the synthesis of cRNA, cRNA was
labeled with biotin and hybridized onto Affymetrix Mouse Genome U74Av2 chip. Gene expression in LSK cells was quantified and averaged from 3 independent experiments. The gene
expression levels were compared between congenic and repective background mice using one way-ANOVA with a statistical cutoff ofp < 0.05. 17 genes are differentially expressed among
all4 strains.
#indicates the genes whose expression is up-regulated by the B6 alleles (high expression in D.B Chr3 and B6 cells) but down-regulated by the D2 alleles (low expression inB.D Chr3 and
D2 cells), whereas
*indicate the genes whose expression is upregulated by the D2 alleles but down-regulated by the B6 alleles.

Example 10
50

Determination of Lxn mRNA Levels in
Hematopoietic Cells
FIG. 6A illustrates Lxn mRNA expression in congenic
LSK cells compared with B6 and D2 cells. In FIG. 6A, an
inverse relationship between Lxn expression and the number
of CAFC day 35 is observed, which confirms the microarray
results both qualitatively and quantitatively. As predicted, B6
alleles in the congenic interval increased Lxn transcripts by
around 3-fold in LSK cells (P=0.00003), and reduced CAFC
day35 numbers by more than half. In contrast, D2 alleles
significantly decreased Lxn expression (P=0.02) and
increased HSC numbers observed in FIG. 6A. Identical number (2x10 5 ) of LSK cells were sorted from each strain and
Lxn mRNA level in these cells was quantified by real-time
PCR and compared between congenic and respective back-
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peripheral blood leukocytes, whole bone marrow, Lin-negative bone marrow cells, and LSK stem cells. In FIG. 6B, the
same number of peripheral blood leukocytes, whole bone
marrow, Lin-negative bone marrow cells, and LSK stem cells
in each of the four strains were evaluated. Two points are
noteworthy from the compiled results of three independent
experiments. First, overall levels ofLxn expression per cell in
each of the populations increase in concert with the content of
primitive hematopoietic cells. Second, Lxn expression per
cell in each of the cell populations accurately reflects the
presence ofB6 (higher expression) or D2 (lower expression)
alleles in the two congenic and background strains. Lxn
expression in differentiated peripheral blood leukocytes
(PB), bone marrow nucleated cells and primitive hematopoietic cell-enriched population, including lineage-negative
cells (Lin-) and HSCs (LSK cells). Lxn mRNA level was
measured by quantitative real-time PCR and shown as mean
(±1 SD) (n=12).
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Quantitative real-time PCR was performed as follows.
Identical numbers (200,000) of cells were used for total RNA
extraction in each type of cell population (peripheral blood,
bone marrow, Lin-negative and LSK cells) for each mouse
strain. Isolated total RNA was reverse transcribed into eDNA
using random hexamers in a TaqMan® reverse transcription
solution (PN N8080234) and stored at -20° C. In real-time
PCR reactions, primer and probe mix for Lxn were purchased
from Applied Biosystems (Foster city, CA, USA). TaqMan®
rodent
glyceraldehyde-3-phosphate
dehydrogenase
(GAPDH) (PN 4308313) served as an endogenous control to
normalize Lxnexpression. PCRreactions were setup according to manufacturer's instructions using TaqMan® universal
PCR master mix (PN 4304437). Analyses of gene expression
were performed in single reporter assays in an ABI PRISM
7700 sequence detection system (PE Biosystems, Foster city,
CA, USA).

tions) and heated at 95° C. for 5 minutes. Samples were then
analyzed by denaturing PAGE (Novex, 10% bis-Tris gel)
using the equivalent of 4x10 5 cells per lane. Following electrophoresis, samples were electro-transferred onto immunobilon-P membranes (Millipore, Bedford, Mass., USA), which
were subsequently blocked and probed with polyclonal rabbit
anti-Lxn Ig-G antibody at a 1:3000 dilution. This antibody
was generated from the Lxn-specific amino acid sequence
CKHNSRLPKEGQAE at the carboxyl terminus, and was
produced by Bethyl Laboratories, Inc (Montgomery, Tex.).
Primary antibodies were detected using alkaline phosphatase-conjugated secondary antibodies (Santa Cruz Biotechnology) and electro-chemifluorescent (ECF) reagent
(Pharmacia Biotech) according to the manufacturer's instructions. Blots were visualized using a Molecular Dynamics
STORM 860 system and Imagequant Software. Following
the detection and quantification of anti-Lxn antibody, immunobilon-P membrane was sequentially stripped in 40%
methanol and the buffer containing 100 mm ~-mercaptoetha
nol, 2% sodium dodecyl sulfate and 62.4 mM Tris-HCl to
remove ECF reaction product and antibodies, respectively.
The stripped membrane was re-probed with anti-actin antibody (Sigma) at 1:500,000 dilution and detected as described
previously.
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Example 12
20

Lxn Protein Levels in Hematopoietic Cells of
Congenic and Background Strain Mice

A rabbit anti -mouse LXN antibody was generated from the
LXN-specific amino acid sequence CKHNSRLPKEGQAE 25
at the carboxyl terminus. Because Lxn transcripts were
present at reasonable levels in unfractionated bone marrow
Example 13
and in Lin-negative cells described above in FIG. 6B of
Example 11, the celllysates derived from these cells were
Cis-Regulation ofLxn Expression
employed for Western blot analysis.
30
Because Lxn expression was detected and quantified in
FIG. 6C illustrates immunoreactivity between the antiLSK cells of the 30 BXD RI strains in the GeneNetwork
mouse LXN antibody and a protein (29 kD) from bone marrow cells by a Western Blot. In FIG. 6C, LXN protein (29
database, a linkage analysis to search for a QTL that could
kDdk) was detected by the anti -lLXN antibody using extracts
modifY Lxn expression was performed. When modifiers of
prepared from B6 and D2 BM samples. Rabbit anti-mouse 35 Lxn expression were queried using such an approach, suggestive linkage (LRS>9. 6) was obtained to a genomic interval
lLXN polyclonal Ig-G antibody was generated from the Lxnspecific amino acid sequence at the carboxyl terminus.
spanning from 56.9Mb to 66.8Mb on Chr 3, very close to the
genomic locations of D3Mit5 and Lxn, a finding consistent
FIG. 6D illustrates the levels ofLXN protein in whole bone
marrow and Lin-negative cells. Consistent with the real-time
with cis-regulation. Moreover, the negative additive effects of
PCR results, Lin-negative cells contain more LXN than bone 40 all markers in this genomic interval suggest that the B6 allele
marrow cells. The cellular content ofLXN in both whole bone
increases Lxn expression, which corroborates our results
marrow and Lin-negative cells was significantly higher in
from microarray, real-time PCR, and Western blot analyses.
mouse strains with B6 alleles at and around the Lxn locus.
Therefore, these results not only suggest the existence of a
The effects of both B6 and D2 Lxn alleles had more promiregulatory element in the upstream region of the Lxn
nent effects on either increasing or decreasing Lxn expres- 45 sequence, but also corroborate D3Mit5 as a marker, presumsion, respectively, when present on opposite strain backably the primary one, for a QTL directly or indirectly responground than in the native context. These results suggest an
sible for the phenotypes conferred by the Chr 3 QTL.
influence of other loci acting through epistatic interactions to
FIG. 7A illustrates various QTLs that may be involved in
optimize Lxn expression in the two strains. Western blot was
the regulation ofLxn expression. In FIG. 7A, a linkage analyperformed on BM nucleated and Lin- cells. The blots (left) 50 sis was performed on GeneNetwork to search for a QTL that
and their quantification (right) profiles demonstrate the difaffects Lxn expression. A genomic region on Chr 3 ranging
ferential expression of Lxn protein in congenic and B6, D2
from 56.9Mb to 66.8 Mb is shown to be associated with the
mice. Actin is used as the control. The blots are from one
Lxn expression with suggestive LRS values (between gray
and pink lines). The linked QTL are listed with corresponding
representative analysis out of 4 independent experiments.
Western blots were performed as follows. Cell samples 55 LRS score and additive effect. The single nucleotide polywere lysed at a concentration of 2x10 7 cells/ml in protein
morphism (SNPs) across Chr 3 are shown as tick marks on the
X-axis.
lysis buffer containing: 10 mM Tris pH7.5, 50 mM NaCl, 30
FIG. 7B illustrates a CpG island analysis in the upstream
mM sodium pyrophosphate, 50 mM NaF, 5 f.LM ZnC1 2 and 1%
sequence of Lxn open-reading frame. Analysis of the
Triton X-100, 2.8 ug/ml aprotinin (Sigma), 1 mM phenylmethylsulfonyl fluoride (Sigma), 1 mM sodium vanadate 60 upstream sequence of the Lxn open reading frame revealed a
(Na3 V04 ) 1 ug/ml pepstatin, and 1 flg/mlleupeptin (Onco164 bp CpG island. Nucleotide sequence of Lxn in upstream
gene Research, MA, USA). Lysate was incubated on ice for
region (-1000 bp) and the first 3 exons (+373 bp) was
obtained from Ensembl database with ID number ENS30 min, and then centrifuged at 15,000xg for 10 minutes to
remove debris. The resulting supernatant was then aliquoted
MUSG0000004 7 557. Transcription start site (TSS) is as indiand stored at -80° C. For Western blot, protein lysates were 65 cated. CpG island search using MethPrimer software showed
thawed and mixed with running buffer and a reducing agent
a 164 bp region (-138 bp to +26 bp) in the upstream of Lxn
(Novex, San Diego, Calif., USA, per manufacturer's instrucsequence enriched for CpG repeats.
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Thus, differential methylation status in the regulatory
region of Lxn may be involved in the differential expression
of Lxn. The results also suggest that Lxn may be a potential
"tumor progenitor gene" which plays an occult role in early
stages of cancer development. Taken together, each of these
possible pathways may be synergistically or independently
involved in the regulation of cycling, apoptosis, and/or selfrenewal of HSCs with entrained consequences for its population size.

duction ofhigh-titer helper-free retrovirus was carried out by
standard procedure in ectotropic Phoenix packaging cells.
Infection of primary murine bone marrow cells were
infected as follows. Primary mouse bone marrow cells were
transduced as previously described with modifications specified below. Briefly, bone marrow cells were harvested from
mice treated 4 days previously with 150 mg/kg body weight
5-fluorouracil (5-FU) (Sigma, St. Louis, Mo.) and cultured
for 24 hours in Dulbecco's modified eagle's medium
(DMEM) supplemented with 10% fetal bovine serum (FBS),
1% penicillin/streptomycin (Gibco Technologies, Carlsbad,
Calif.), 50 ng/mL recombinant mouse stem cell factor
(mSCF), 10 ng/mL mouse interleukin 6 (miL-6), and 10
ng/mL mouse interleukin 3 (miL-3) (R&D Systems, Minneapolis, Minn.). The cells were then harvested and slowly
spread on the top surface of the membrane of a Transwell
insert (Corning Incorporated Life Sciences, Acton, Mass.) at
a density of 2x 10 6 cells per well. The viral supernatants were
added to the Transwell inserts along with 4 flg/ml of polybrene and were cultured with cells for further 48 hours. The
viral supernatant was changed 3 times during this period of
time. The recovered cells were then transplanted into sublethally-irradiated (600 Rad) recipient mice at a dose of at
least 1x 10 6 cells per mouse. Around 12 weeks after transplantation, retrovirally-transduced, i.e. GFP positive, bone marrow cells were flow cytometrically sorted from primary
recipient mice using a FACSVantage (Becton-Dickinson) and
used for CAFC assay and limiting-dilution competitive
repopulation assay.
Functional analysis of retrovirally-transduced cells were
performed as follows. Identical numbers of bone marrow
cells transduced with either the GFP control vector or the
Lxn-GFP vector were sorted from the primary recipient mice.
The CAFC and limiting-dilution competitive repopulation
assays of these GFP positive cells was performed as described
above. The HSC frequencies (CAFC day35 and LTRC) were
calculated and compared to measure the effects ofLxn overexpression on HSC number.
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Example 14
A Decrease in Stem Cell Numbers By the
Overexpression of Lxn
15

Because D2 and B.D Chr3 congenic mice have lower levels
ofLxn expression and higher stem cell numbers, Lxn expression in both strains were enhanced in both strains to test the
effect ofLxn overexpression on stem cell numbers.
FIG. SA illustrates a schematic for in vitro infection of
bone marrow cells with retroviral vectors containing either
GFP or Lxn (Lxn-GFP), and subsequent transplantion into
irradiated mouse recipients. At ;;:12 weeks following transplant, when all hematopoiesis originated from transplanted
stem cells, the bone marrow was harvested from the primary
recipients and cells expressing GFP were sorted using flow
cytometry. The GFP-positive population was isolated to be
assayed for CAFC day35 content in D2-derived cells and for
LTRC frequency in B.D Chr3-derived cells. In FIG. SA, the
structure of Lxn-containing retroviral vector is shown in
which the Lxn-GFP represents the Lxn-containing vector;
GFP represents the no insert control.
FIG. SB illustrates results of a Western blot analysis of
GFP+ cells sorted from the BM of the recipient mice transplanted with either Lxn-GFP or GFP-transduced cells.
Expression levels of Lxn protein in bone marrow cells transduced with Lxn-GFP were higher than the expression levels
ofGFP-transduced cells, confirming that both Lxn transcript
and protein levels were dramatically increased in Lxn-GFP
cells.
FIG. SC illustrates results ofCAFC day35 frequency assay
ofD2 bone marrow cells transduced with either GFP control
or Lxn-GFP. * P=0.0059 (t-test, one-tail).
FIG. SD illustrates results of long-term repopulating cells
(LTRC) frequency assay of B.D Chr.3 congenic BM cells
transduced with either GFP control or Lxn-GFP. * P=0.0458
(t-test, one-tail).
In FIGS. SC-SD, the frequency of primitive stem cells was
significantly reduced (P<O. 05) in the population infected with
the Lxn-GFP vector relative to cells infected with the GFP
control vector. Approximately a 3-fold decrease in HSC numbers in Lxn-overexpressing cells reflects precisely the difference between two parental B6 and D2 strains. Therefore,
these results further confirm Lxn as the primary quantitative
gene negatively regulating HSC numbers.
Retroviral vectors were constructed as follows. The retroviral vector, Sfbeta 91, served as a control and the backbone
for cloning of Lxn eDNA. It contained the 5'-long terminal
repeat (LTR) derived from myeloproliferative sarcoma virus
(MPSV) and a 3'-LTR derived from spleen focus forming
virus (SFFV). The internal ribosomal entry site sequence
derived from the encephalomyocarditis virus was used for
simultaneous translation of gene insert and the gene for
enhanced green fluorescent protein (GFP). The Lxn eDNA
sequence was cloned upstream of the IRES of the Sfbeta91
vector (MPSV-IRES-GFP-SFFV) to create a recombinant
Lxn-carrying vector (MPSV-Lxn-IRES-GFP-SFFV). Pro-
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Example 15
Inhibition of Latexin by Exemplary SiRNAs
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FIG. 9A illustrates exemplary SiRNAs transfected into
NIH3 T3 cells, as described in Example 15. FIG. 9B illustrates
the results of sequence-specific SiRNA-mediated inhibition
of latexin mRNA expression in mouse adult stem cells that
resulted in HSC proliferation and HSC apoptotic inhibition,
as described in Example 15. For latexin-specific inhibition,
three exemplary SiRNA were ordered from Ambion (Austin,
Tex.) identified by the following IDs: SiRNA! (724142) designated as SEQ ID N0:3 (5'-UCUUCCUGGGAUAU
CCUCC-3'); SiRNA2 (72510) designated as SEQ ID N0:4
(5'-UAAGAUGGUACUUGUG CCC-3'); and SiRNA3
(72605) designated as SEQ ID N0:5 (5'-AAAAUUGUCUGGGAUGUC C-3'). A sequence in 3' untranslated region
was used as a negative control "SiRNA NC" designated as
SEQ ID N0:6 (5'-AUGCAGCUCGGUACUGUAG-3'). For
each type of SiRNA, the sense and anti-sense RNA oligonucleotides were diluted to 200 uM concentration. For the
annealing reaction, 40 ul of each oligonucleotide were mixed
with 20 ul of annealing buffer (Ambion) and heated for 1
minute at 90° C., followed by an incubation for 1 hour at 37°
C. For the transfection, the double-stranded RNA oligonucleotides were further diluted at 20 pmol/ul concentration. For
the transfection of NIH3T3 cells with SiRNA and reported
GFP plasmid, approximately 4xl0 5 NIH3T3 cells were seed
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in a 6-well plate and were grown overnight in Iscove's Modified Dulbecco's Medium (IMDM) (Invitrogen) containing
10% fetal bovine serum (FBS). The cells were 8090% confluent at the time oftransfection. For each transfection/well,
approximately 9 ul Lipofectamine™ 2000 (Invitrogen) were
diluted with 250 ul Opti-MEM I Reduced Serum Medium
(Gibco) and incubated for 5 minutes at room temperature.
Approximately 2 ug of reporter GFP plasmid and 200 f.tmol of
SiRNA were also diluted in 250 ul ofOpti-MEM I Reduced
Serum Medium. The diluted Lipofectamine™ 2000 were
combined with the diluted SiRNA and the reporter plasmid.
The mixture was incubated for 20 minutes at room temperature. The NIH3T3 cells were washed twice with PBS (Invitrogen) and incubated with 500 ul of RNA-reporter plasmidLipofectamine™ 2000 complex in each well. 12-15 hours
after incubation, the medium was changed to IMDM plus
10% FBS. The cells were detached by trypson and resuspended into 5 ug/mL propidium (PI) solution. For sorting
transfected (GFP+) cells, flow cytometric analysis was performed on a dual-laser FACSVantage (Becton Dickinson
Immunocytometry Systems, San Jose, Calif.) to select PI
negative and GFP positive cells.
Quantitative real-time PCR was performed in the following manner. Identical numbers (200,000) of cells were used
for total RNA extraction in cells transfected with 3 SiRNAs
and negative control RNAs. Isolated total RNA was reverse
transcribed into eDNA using random hexamers in a Taq-

Man® reverse transcription solution (PN N8080234) and
stored at -20° C. Quantitative real-time PCR analyses of
selected genes were performed in single reporter assays with
anABI PRISM 7700 sequence detection system (PE Biosystems, Foster city, CA, USA). PCR reactions were set up
according to manufacturer's instructions using TaqMan®
universal PCR master mix (PN 430443 7), and the primer and
probe mixes for each tested gene were purchased from
Applied Biosystems (Foster city, CA, USA). TaqMan®
rodent
glyceraldehyde-3-phosphate
dehydrogenase
(GAPDH (PN 4308313) served as an endogenous control to
normalize gene expression. The analysis of gene expression
was performed by the relative standard curve method. In
brief, standard curves were prepared for the GAPDH control
and for each of tested genes, and the amount of GAPDH
control and test gene were determined from the standard
curve. A normalized test gene value was determined relative
to GAPDH expression. Each biological sample was obtained
from at least 5 mice, and each sample was run with at least 5
replicates within an experiment. Three replicate biological
experiments were performed in each strain.
It will be appreciated that, although specific embodiments
of the invention have been described herein for purposes of
illustration, various modifications may be made without
departing from the spirit and the scope of the invention.
Accordingly, the invention is not limited except as by the
appended claims.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

SEQ ID NO 1
LENGTH, 1113
TYPE, DNA
ORGANISM, human

<400> SEQUENCE,

1

agaagcagtc agcccagggc tctcggatgc agggagcctg ggcccaaaca gcagcttccg

60

gagtcggaag gagctgagga agaagacaga ctgaaggagc ttgcgacttt tccgcctcgg

120

caaccggacc cagcagcaag caggacgggc ggcgctctgc tactggtccc gttaagccag

180

agtagcccaa gccctgaagt cactgctcat ccggaatgga aatcccgccg accaactacc

240

cagcctccag ggcggccttg gtggcacaga actacatcaa ctaccagcag gggaccccgc

300

acagggtgtt tgaggtgcag aaggtcaaac aagccagcat ggaggatatt ccaggaagag

360

gacataagta tcgccttaaa tttgctgttg aagaaattat acaaaaacaa gttaaggtga

420

actgcacagc tgaagtactt tacccttcaa cgggacaaga aactgcacca gaagtcaact

480

tcacatttga aggagaaact ggaaagaatc cagatgaaga agacaacaca ttttatcaaa

540

gacttaagtc catgaaggaa ccgctagaag cacaaaatat tccagacaat tttggaaatg

600

tatctccaga aatgacgctc gttctacatt tagcctgggt tgcctgtggt tatataatat

660

ggcaaaattc tactgaagac acatggtata aaatggtaaa aattcaaact gtcaagcaag

720

tgcaaagaaa tgatgacttt attgaattag actacaccat tctacttcat aatatagcat

780

ctcaggagat tattccctgg caaatgcaag ttctctggca tccacaatac ggcactaaag

840

taaaacataa tagccgtctg ccaaaggaag tacaactgga ataaacaaaa accctaacac

900

tggaagtgta aacatgtcta ttgatgtgta tgccaatttc actggcatct agcttatgag

960

gccaaataat cccaaagtgt cactttatat aaatgtcttg attacagtat agaactttat

1020
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33
-continued
agagtccata atacaaagta tcactacata aaaatgtctt taaaacagta atagtggtat

1080

gtatatccaa aataaaaagc ttcaatttca gee

1113

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 222
TYPE, PRT
ORGANISM, human

<400> SEQUENCE,

2

Met Glu Ile Pro Pro Thr Asn Tyr Pro Ala Ser Arg Ala Ala Leu Val
1
5
10
15
Ala Gln Asn Tyr Ile Asn Tyr Gln Gln Gly Thr Pro His Arg Val Phe
20
25
30
Glu Val Gln Lys Val Lys Gln Ala Ser Met Glu Asp Ile Pro Gly Arg
35
40
45
Gly His Lys Tyr Arg Leu Lys Phe Ala Val Glu Glu Ile Ile Gln Lys
50
55
60
Gln Val Lys Val Asn Cys Thr Ala Glu Val Leu Tyr Pro Ser Thr Gly
65
70
75
80
Gln Glu Thr Ala Pro Glu Val Asn Phe Thr Phe Glu Gly Glu Thr Gly
85
90
95
Lys Asn Pro Asp Glu Glu Asp Asn Thr Phe Tyr Gln Arg Leu Lys Ser
100
105
110
Met Lys Glu Pro Leu Glu Ala Gln Asn Ile Pro Asp Asn Phe Gly Asn
115
120
125
Val Ser Pro Glu Met Thr Leu Val Leu His Leu Ala Trp Val Ala Cys
130
135
140
Gly Tyr Ile Ile Trp Gln Asn Ser Thr Glu Asp Thr Trp Tyr Lys Met
145
150
155
160
Val Lys Ile Gln Thr Val Lys Gln Val Gln Arg Asn Asp Asp Phe Ile
165
170
175
Glu Leu Asp Tyr Thr Ile Leu Leu His Asn Ile Ala Ser Gln Glu Ile
180
185
190
Ile Pro Trp Gln Met Gln Val Leu Trp His Pro Gln Tyr Gly Thr Lys
195
200
205
Val Lys His Asn Ser Arg Leu Pro Lys Glu Val Gln Leu Glu
210
215
220

<210> SEQ ID NO 3
<211> LENGTH, 19
<212> TYPE, RNA
<213> ORGANISM: artificial sequence

<220> FEATURE,
<223> OTHER INFORMATION, mouse
<400> SEQUENCE, 3
ucuuccuggg auauccucc

19

<210> SEQ ID NO 4
<211> LENGTH, 19
<212> TYPE, RNA
<213> ORGANISM: artificial sequence

<220> FEATURE,
<223> OTHER INFORMATION, mouse
<400> SEQUENCE, 4
uaagauggua cuugugccc

19
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35
-continued
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 5
LENGTH, 19
TYPE, RNA
ORGANISM: artificial sequence
FEATURE,
OTHER INFORMATION, mouse

<400> SEQUENCE, 5
19

aaaauugucu gggaugucc

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 6
LENGTH, 19
TYPE, RNA
ORGANISM: artificial sequence
FEATURE,
OTHER INFORMATION, mouse

<400> SEQUENCE,
19

augcagcucg guacuguag

We claim:
1. A method for reconstituting a recipient host with a population of hematopoietic stem cells (HSCs) generated in vivo,
the method comprising: administering to the recipient host a
pharmaceutical composition comprising an antagonist that
reduces the expression and/or the activity oflatexin, wherein
the recipient host is affected with at least one condition
selected from the group consisting of: a disease of the bone
marrow, a cancerofthe blood, a cancerofthe bone marrow, an
immunological disorder, thalassemia major, sickle-cell disease, and myelodysplastic syndrome, wherein the antagonist
can promote HSC proliferation by at least 25%, wherein

25

30

latexin includes a latexin polynucleotide variant and/or a
latexin polypeptide variant that interacts with the antagonist,
and wherein the latexin polynucleotide variant has at least
95% sequence identity to the full length of SEQ ID NO: 1 and
the latexin polypeptide variant has 100% sequence identity to
the full length of SEQ ID NO: 2.
2. The method of claim 1, wherein the recipient host is
affected with at least one condition selected from the group
consisting of leukemia, lymphoma, and multiple myeloma.
3. The method of claim 1, wherein the latexin polynucleotide variant encodes SEQ ID NO: 2.

* * * * *

